BioTOP-Report

2014Biotech and Pharma in Berlin-Brandenburg

BioTOPics 47 | May 2014 BioTOP-Report 2014

EditorialThe German Capital Region – Biotechnology and Life Sciences are Ready for the Future 3

BiotechnologyThe Capital Region – New Jobs and New Companies 4

PharmaAttractive Location 14

GlycoscienceGlyco Research for Innovations in Health Industry 18

Bioelectronics The Joint Lab Bioelectronics – A New Platform for the Integration of Microelectronics into Life Sciences 20

Business LocationExcellent Services for Berlin-Brandenburg 24

Spotlight on European Business and InternationalizationThe Enterprise Europe Network Berlin-Brandenburg 26

Biotech ParksThe BioCampus Network Berlin-Brandenburg 34 Addresses 39

Publisher: Berlin Partner für Wirtschaft und Technologie GmbH · BioTOP Berlin-BrandenburgFasanenstraße 85 · 10623 Berlin · Germany · Phone +49 30 318622–0 · Fax +49 30 318622–22 · biotop@biotop.de · www.healthcapital.de

Editor: Volker ErbDesign & Production: webersupiran.berlinTranslation: Kate Abbott · Berlin

Photos/Figures: BioTOP or authors and: Page 14 Paulus Rusyanto/dreamstime.com, Sean Pavone/dreamstime.com Page 21 Warenemy/dreamstime.com, Collpicto/dreamstime.com Page 27 adimas/Fotolia (Profile Alacris), Noah Clayton/co.don (Profile co.don) Page 30 Werner Popp (Profile organobalance).

Content

3

BioTOPics 47 | May 2014 BioTOP-Report 2014

Editorial

The German Capital Region – Biotechnology and Life Sciences are Ready for the Future

Berlin-Brandenburg is an extremely attractive location for research and its translation into industrial applications. The establishment of the Berlin Institute of Health, successful spin-offs and inward investment show that the Ger-man capital region provides top conditions for the healthcare industry. Berlin is the start-up capital of Germany!

With its new “Healthcare Industries” master plan, the capital re-

gion is setting the course for the sector’s development until 2018.

Basic research, innovation, spin-offs and application – in the fu-

ture, these will remain the four pillars that determine the success-

ful implementation of the cluster strategy in Berlin-Brandenburg.

Biotechnology/pharmaceuticals, medical technology and the

healthcare industries are the focal areas. In the coming years,

biotechnology/pharmaceuticals development will feature:

The creation of new translation platforms in basic research,

clinical research and industrial biotechnology

Max Planck and Fraunhofer Research, as well as the Helmholtz

and Leibnitz Institutes, are drivers of technology transfer and pio-

neers of innovative technologies and products.

Concentration on therapy development through new system

medicine strategies

The Max Delbrück Center for Molecular Medicine and Charité –

Universitätsmedizin Berlin are the umbrella for the new flagship of

German biomedicine.

In diagnostics, focus on the development of companion diag-

nostics

Laboratory medicine, applied research, SMEs and the pharma-

ceuticals industry are pooling their activities for therapy optimiza-

tion in personalized medicine.

In regenerative medicine, concentration on the development of

new cell therapies

The Berlin-Brandenburg Center for Regenerative Therapies

(BCRT), biotechnology SMEs and pharmaceuticals partners in

the international Regenerative Medicine Coalition are part of a

high-performance product development network.

Focus on the sustainable use of biological resources for medi-

cal applications in industrial biotechnology

The Leibniz Institute for Agricultural Engineering, university-related

research and biotechnology SMEs are successfully implementing

the federal government’s bioeconomics strategy and contributing

to the strength of the healthcare industries.

Development of new growth fields in the life sciences with inter-

disciplinary technologies

Cross innovation at the interface of microsystems technology, mi-

croelectronics, photonics and surface engineering and thin films

open up completely new opportunities for analytics, automation

and hardware development and along with this, for growth, value

creation and cost reduction.

Value chain expansion via inward investment and industrial

location expansion

With more than 200 biotechnology companies, over 30 research

institutions and over 130 clinics and hospitals, Berlin-Branden-

burg is already a European hot spot for the life sciences. Growth

in expertise, players and investment will reinforce the capital re-

gion’s leading position in the international markets.

This new edition of the BioTOP Report provides you with an ex-

citing, informative overview of the development in the capital re-

gion’s industries. With themes such as glyco-engineering technol-

ogy and bioelectronics, it underscores internationally outstanding

activities. We wish you reading pleasure and invite you to commit

to Berlin-Brandenburg as a place to develop your business.

Reach out and contact us!

Prof. Dr. Peter Seeberger Dr. Günter Peine

Expert Circle Spokesman Head of

“Biotech/Pharma“ BioTOP Berlin-Brandenburg

4

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

JANUARY 2013Epigenomics AG hands in fourth module at FDA completes application for approval as planned +++ co.don® AG applied for approval of joint cartilage product chondrosphere® in the EU +++ Shire discovered the Munich-based RNA specialist Ethris for itself. In cooperation the two companies want to find therapies for rare diseases

FEBRUARY 2013Epigenomics receives notice about grant of priority review status and accep-tance of the hand-in of the PMA application for Epi proColon® from the FDA +++ Innovation forum “Biopolymers and Bio-based Plastics” in Schwarz heide

MARCH 2013BIOTECON Diagnostics GmbH extends its robot segment +++ Epigenomics AG collects 5,0 million Euros through capital increase +++ New research collective INNO-TRACE develops innovative contrast agents for tumour imaging

APRIL 2013Europe's largest clinical laboratory at Campus Virchow-Klinikum: Labor Berlin inaugurates new site

MAY 2013Bayer HealthCare presents new incubator model for biotech start-ups in Berlin

JUNE 2013Alacris Theranostics GmbH announces Illumina CSPro certificate for next gen-eration sequencing +++ Humedics co-founder Martin Stockmann receives Von-Langenbeck Prize for development of LiMAx test

JULY 13Berlin-Brandenburg Healthcare Industries cluster HealthCapital launches new website: www.healthcapital.de +++ Caprotec expands alliance with Bayer +++ EZAG AG in participation via subsidiary OctreoPharm Sciences GmbH +++ cap-rotec bioanalytics GmbH and Bayer CropScience enter into second research collaboration +++ NOXXON Pharma completes patient recruitment for phase IIa study in diabetic nephropathy +++ Romer Labs® and the Institute for Product Quality (ifp) launch new AgraQuant® F.A.S.T.

AUGUST 13Bayer HealthCare concludes partnership and license agreement with Compu-gen Ltd. for the research, development and marketing of antibody-based drugs for cancer immunotherapy. +++ caprotec bioanalytics GmbH and Syngenta Inter-national AG announce research collaboration +++ Epigenomics AG agreement with YA Global Master SPV Ltd. brings funding of up to €5 million

SEPTEMBER 13Eckert & Ziegler BEBIG s.a. takes over prostate cancer implantation business of American company Biocompatibles Inc. for $5 million +++ Myelo Therapeutics GmbH successfully completes funding round for the development of adjuvant cancer therapy

OCTOBER 13Epigenomics and Polymedco sign commercialization agreement for Epi proCo-lon® for the North American market +++ Sugar is life: GlycoUniverse successfully launched in Campus Buch +++ Cell Medica, a leading company in the T-cell

Biotechnology

The Capital Region – New Jobs and New Companies

The growth trend of recent years continues in 2013. Employee numbers have grown by 5.6 % (last year, 6.5 %). Currently, 232 companies employ 4,586 people. The constant momentum is accompanied by many newly founded businesses.

k According to the latest BioTOP survey, 232 biotechnology

companies are active in the Berlin-Brandenburg region. This

means the company base has expanded by a total of 10

companies against last year.

k A total of 14 companies have stopped doing business in the

region, either shutting down completely or relocating.

k The addition of 24 companies more than compensated for

this loss. Of the new companies, we count 6 additions due

to inward investment and new registration and – particularly

notable – 18 start-ups.

k The current base of 232 companies has created 352 new jobs.

This translates into a growth rate of over 8 percent.

k After subtracting the 114 jobs lost due to business shut-downs,

the sector in the region gained a total of 273 jobs, adding up

to regional employment growth of 5.6 % in the sector.

For many years, biotechnology region Berlin-Brandenburg has

been on a steady growth course. One of the sector’s leading re-

gions in Germany and Europe, it hosted 18 start-ups last year

alone – a figure to note. This speaks volumes in favor of the loca-

tion’s general conditions and the commitment of the many players

involved and their start-up-related activities. And above all, un-

derscores the courage of the many company founders who are

seeking their fortune in this highly sophisticated sector.

Smaller companies dominate the region’s business landscape:

139 companies in the sector have less than 10 employees. Only

13% of the total jobs are located in these companies, however.

Over 53% of the sector’s employees in the region work for the 19

companies with more than 50 employees.

The majority of these companies (88%) focus on the areas of new

therapeutic agents, diagnostic products and biopharmaceuticals

services; followed by 19% in the agriculture/food sectors and 13%

in the industrial biotechnology sector (multiple mentions).

The start-ups still have little effect on the job market. At their

launch, none of these companies had more than 10 employees.

5

BioTOPics 47 | 6. Juni 2014 (3:02) BioTOP-Report Biotechnology

Key milestones achieved

MOLOGEN completed a successful fiscal year 2013 with three

different product candidates in clinical development for the first

time. The final evaluations for the completed clinical trials of

MGN1703 and MGN1601 provided very positive data, and with

MGN1404 (a product that combats malignant melanoma), the

company launched the clinical development phase of another

product candidate within the framework of a partnership, contrib-

uting to an expansion of its pipeline. For its most advanced prod-

uct candidate, the cancer immunotherapy MGN1703, MOLOGEN

was also able to present very positive clinical data from the final

evaluation of a phase II trial in colorectal cancer (IMPACT study)

in 2013. For the most part, the preparations for a phase III pivotal

study in this indication were completed in the course of the last

fiscal year.

Glycotope specializes in the glycosylation of proteins. Glycotope

has a broad portfolio of drugs in clinical development, including

the new cancer drugs, PankoMab-GEX™ and CetuGEX™, both

in phase IIb trials. PankoMab-GEX™ is the first fully glycosylated

and glyco-optimized human antibody for a novel tumor-specific

carbohydrate-protein mixed epitope (TA-MUC1) abundantly pres-

ent in a larger set of tumor indications, metastases and cancer

stem cells. Additional Glycotope products include TrasGEX™,

which has successfully completed its phase I/IIa trial and the im-

proved fertility hormone FSH-GEX™, which is expected to begin

two phase III clinical trials in 2014.

Biopharmaceuticals company NOXXON Pharma is a pioneer in

the development of a new class of proprietary therapeutic agents

called “Spiegelmers,” which are chemically synthesized L-ste-

Dr. Matthias Schroff

CEO MOLOGEN AG

We are well aware that our company’s success is also due to

the conditions that Berlin and the capital region offer. Wheth-

er research collaboration (FU Berlin) or clinical studies with

Charité Universitätsmedizin and its departments – we benefit

from the close scientific network. The availability of qualified

personell is also a key advantage, which surely ties into the

high quality of life in Berlin. Berlin is a city for conferences

and conventions and many of our sector associations have

their headquarters here. This is another reason why Berlin is

an excellent location for medical biotechnology. As a research

company, we appreciate the fact that Berlin is one of the

world's leading regions and innovative locations in the field

of life sciences.

therapy field, opens a central European production facility in Berlin-Buch +++ ProBioGen upholds strong patent position in viral vaccine manufacturing field

NOVEMBER 13Glycotopes Fully Human and Glycooptimized Recombinant FSH-GEX exhibits superior activity and excellent tolerability in phase II clinical trial for in vitro fertilization +++ The methylated SHOX2 biomarker from Epigenomics shows promising results for therapy-related monitoring of lung cancer patients +++ SCIENION´s sciFLEXARRAYER receives product technology innovation award from Materials Science Society AVS +++ The NeuroPro Alliance, a joint ven-ture between the Technical University of Applied Sciences Wildau, nanoPET Pharma GmbH and AudioCure Pharma GmbH, receives research award.

DECEMBER 13OMEICOS Therapeutics: new drug for atrial fibrillation in model systems tests positively +++ Contichrom® systems from KNAUER receive Berlin-Branden-burg Innovation Award +++ ProBioGen announces expansion of commercial licenses with emergent biosolutions for AGE1.CR® viral vaccine manufacturing production platform

JANUARY 14Improved diagnostics for sepsis-associated liver dysfunction with LiMAx test from Humedics GmbH +++ Epigenomics starts trading on US OTCQX mar-ket +++ Cell Medica announces European Union orphan drug designation for Cytovir ADV +++ ward-winning Ostendum Lab-on-a-Chip nanodevices are pro-duced with SCIENION's sciFLEXARRAYER SX

FEBRUARY 14The Swedish-German company Amal Therapeutics SA has acquired investors for a seed financing round +++ mivenion GmbH receives FDA approval for Xiralite® Fluorescence Imaging System X4 for microcirculation visualization +++ €15 million for Mologen

MARCH 14Glycotope GmbH raises €55 million +++ FDA Advisory Committee Provides Recommendations for Epigenomics' Colorectal Cancer Screening Blood Test

APRIL 14Alacris Theranostics GmbH announces partnership with Walldorfer SAP AG +++ On May 14, Bayer HealthCare opened its first German CoLaborator in Berlin-Mitte on the company's premises +++ Bayer Pharma AG participates in the High-Tech Startup Fund II +++ International pharmaceutical company Takeda extends production facility in Oranienburg

6

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

0

100

200

300

400

500

600

700

800

900

1.000

1.100

1.200

1.300

1.400

1.500

1.600

1.700

1.800

1.900

2.000

2.100

2.200

2.300

2.400

2.500

139 companies 1-10 employees

Number of Employees According to Company Size

74 companies 11-50 employees 19 companies > 51 employees

'04 '05 '06 '09 '10 '11 '12 '13'07 '08 '04 '05 '06 '09 '10 '11 '12 '13'07 '08 '04 '05 '06 '09 '10 '11 '12 '13'07 '08

Nu

mb

er

of

em

plo

yee

s

602

1.542

2.442

In comparison to the previous year, the average number of employees per company decreased by 9,2 % in the 1-10 category and increased 15,9 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 3,7 %. (Source: Own survey, BioTOP database, 232 companies questioned, February 2014)

reoisomer RNA aptamers and a non-immunogenic alternative

to antibodies. NOXXON is approaching the completion of multi-

ple proof-of-concept studies with a diversified portfolio of clini-

cal-stage Spiegelmer® therapeutic agents exhibiting high safety

and tolerability, and promising signs of efficacy. Emapticap pegol

(NOX-E36), an anti-CCL2/MCP-1 Spiegelmer®, is currently in a

phase IIa study in patients with diabetic nephropathy. Olaptesed

pegol (NOX-A12), an anti-CXCL12/SDF-1 Spiegelmer®, is cur-

rently in phase IIa studies in two hematological cancers: multiple

myeloma and chronic lymphocytic leukemia. Lexaptepid pegol

(NOX-H94), an anti-hepcidin Spiegelmer®, has shown efficacy in

a subset of anemic cancer patients with functional iron deficiency

in a pilot study where the pharmacodynamic parameters of iron

metabolism and erythropoiesis were positively influenced and

hemoglobin levels increased following lexaptepid mono-therapy.

The product will also be evaluated in a phase IIa study in dialysis

patients with ESA-hyporesponsive anemia.

7

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

0

500

1.000

1.500

2.000

2.500

3.000

3.500

4.000

4.500

5.000

'13

Employees in Biotech SMEs

'04 '05 '06 '09 '10 '11 '12'07 '08

Nu

mb

er

of

em

plo

yee

s

4.586

Employment rose to 4.586 in 2013. This is a growth of 5,6 % in comparison to the previous year. The number of companies went up to 232, reflecting the arrival of 24 companies (18 start-ups) and 14 departures. (Source: Internal survey, BioTOP database, 232 companies questioned, February 2014)

Epigenomics, a molecular diagnostics company in the process

of developing and commercializing a pipeline of proprietary

products for the screening and diagnosis of cancer, announced

the outcome of a meeting of the Molecular and Clinical Genetics

Panel of the FDA’s Medical Devices Advisory Committee held in

conjunction with its premarket approval for its blood-based col-

orectal cancer screening test Epi proColon®. The members of the

Medical Devices Advisory Committee voted favorably, determin-

ing that the benefits of Epi proColon® do outweigh the risks for use

in patients who meet the criteria.

Caprotec bioanalytics and Syngenta International AG announced

a joint research agreement in which Syngenta will gain access

to caprotec’s proprietary capture compound mass spectrome-

try technology. The companies will work together to profile the

interactions of one of Syngenta’s novel active compounds with

the proteome in its relevant plant biological system. caprotec’s

platform enables the unbiased evaluation of the interactions of

small molecules with protein mixtures in a targeted and directed

manner, which facilitates the identification and elucidation of trac-

table targets and accelerates the development of promising leads.

Cell Medica announced that the European Medicines Agency

(EMA) Committee for Orphan Medicinal Products has issued a

positive opinion on an application for orphan designation of a

novel T cell immunotherapy under development by the company.

The cell therapy Cytovir ADV targets the treatment of adenovirus

infections in patients following allogeneic hematopoietic stem cell

(bone marrow) transplant. It is comprised of adenovirus-specific T

cells derived from allogeneic donor leukocytes, expanded ex vivo.

co.don is one of the world’s leading specialists in the cultivation

of cells for the joint-preserving treatment of articular cartilage and

intervertebral disk defects. Using the company’s patented thera-

peutic products, doctors are able to avoid joint and intervertebral

disk prostheses in many cases. An increasing number of orthope-

dists, orthopedic surgeons and neurosurgeons are relying on this

regenerative therapeutic procedure. This minimally invasive meth-

od for articular cartilage regeneration has been successful with

approx. 6,000 patients in Germany. Experts estimate the overall

European market to have a potential annual worth of approx. €1.2

billion. With its current infusion of capital, co.don is paving the

way for the EU-wide approval of its biological therapeutic co.don

chondrotransplant® DISC – an autologous method for treating in-

tervertebral disk damage.

MetrioPharm was able to complete the regulatory pre-clinical

study package. The most important outcome was MP1032’s

superior safety profile as confirmed by the results from the var-

ious regulatory pharmacology and toxicology studies conducted

throughout the past year. The results of these tests surpassed

all ambitious expectations. Repeated daily administration of up

to 150(!) times the normal therapeutic dose for 28 consecutive

days did not cause any side-effects or adverse events whatsoever.

A clean safety profile is a highly valuable asset for a new drug.

With the impeccable animal safety data obtained for MP1032 an

important foundation for entering clinical Phase I trials in 2014

was laid. For the first time, MP1032 can now be tested directly in

humans.

8

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

ProBioGen is an internationally operating technology provid-

er and contract development and manufacturing organization

(CDMO) with almost 20 years of experience in cell culture, pro-

cess development and GMP manufacturing. A competent and

reliable CDMO partner, ProBioGen offers customized solutions

for even the most challenging development and manufacturing

requirements. ProBioGen has signed its latest GlymaxX® ADCC

technology deal with a top-10 pharmaceuticals company for a

therapeutic antibody platform.

Investment in the Region

In recent months, these companies have acquired financing of

almost €100 million. Glycotope GmbH has led the field with a

new financing round of €55 million. Investors have supplied the

company with €130 million in the past few years. One of the larg-

est in Europe, the latest round of financing has attracted inter-

national attention. It will be exciting to see how Glycotope’s fu-

ture develops. The listed companies have also obtained a new

infusion of money. Mologen and Epigenomics have been able to

financially safeguard their next steps with new capital increases,

for example. High-Tech Gründerfonds (HTGF) and IBB Beteiligu-

ngsgesellschaft, one of the most active venture capital financiers

in Germany, were among the most responsive financiers in the

early-stage area again in 2013. Subsidies from the states of Ber-

lin and Brandenburg, which contributed project-related funding

volumes of 42 Mio. Euro to life sciences companies alone, supple-

mented private funding. Investment helps not only the companies

involved, but is also relevant for the development of the overall

biotechnology region, generating useful growth effects above and

beyond its benefits to individual companies.

Conclusion

The Berlin-Brandenburg biotechnology region has enjoyed a con-

stant growth trend for years. The companies in the sector have

again proven their competitiveness in 2013/2014. After many years

of developing products and conducting the studies required by

the certifying authorities, the near future will show whether the

investments have paid off. Most of the biopharmaceutical com-

panies are doing so well that is safe to be optimistic, although the

risk remains high. The region’s pool of highly specialized service

providers is only one of the factors upon which this excellent eco-

nomic development is based. The companies in the sector grow

organically and are typically less dependent on external investors.

They important sector delivers constant, sustainable growth for

the Berlin-Brandenburg region.

Relatively strong fluctuation is typical of the still-young biotech-

nology sector. Established companies go and new ones come to

take their place. The high number of start-ups, which ultimately

compensate for failed business ventures, is another reason for

optimism. To ensure the successful development of these young

companies, private investors must actively participate in ear-

ly-stage financing again.

Dr. Karen Uhlmann

COO/Co-CEO Omeicos Therapeutics GmbH

Dr. Robert Fischer

CSO/Co-CEO Omeicos Therapeutics GmbH

OMEICOS Therapeutics is working on a new drug for the treatment of atrial fibrillation, and would like to implement the clinical devel-

opment by the end of 2016. The demand for a new atrial fibrillation treatment is high – and with it, its commercial potential. All of the

medicines available now to the majority of patients have a limited effect, and some of them go hand in hand with highly problematic

side effects. Working with their partners at the Texas Southwestern Medical Center, scientists at the Max Delbrück Center for Molecular

Medicine (MDC) Berlin-Buch have identified a metabolism product of the Omega 3 fatty acid with an anti-arrhythmic effect. Based on

this product, they have synthesized drug candidate OMT-33. The fact that the active ingredient can be further developed for commer-

cial use as part of a start-up is due to the very good general conditions existing before the company was even established. OMEICOS

received its initial financial support from the MDC PreGO-Bio funds and Helmholtz Enterprise, the spin-off support project of the

Helmholtz Association. The company received seed financing through a High-Tech Gründerfonds participation and ProFIt funding

from the state of Berlin, which is co-funded with capital from the European Fund for Regional Development (EFRE). With its BioTech

Park, Campus Berlin-Buch provides the ideal framework conditions and an outstanding infrastructure for our product development

phase. Of course the direct proximity to MDC is essential to our success. OMEICOS and MDC will continue to work in close partner-

ship. And our cooperation with the Campus' BBB Management GmbH also makes the location very attractive for us.

vfa bio represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies (vfa). vfa campaigns for the interests of 45 worldwide leading pharmaceutical companies in the fields of health, research and economy.

vfa bio seeks to exploit the therapeutic and economic potential of bio-technology to make Germany the leading biotech location in Europe.

Medical biotechnology is vfa bio’s topic. We primarily deal with:

▪ Medical progress provided by biopharmaceuticals - benefit for patients, physicians and society as a whole

▪ Access to biopharmaceuticals for patients

▪ Business location Germany and regulatory and economic framework for research, development and production of biopharmaceutical

▪ Biosimilars

▪ Orphan medicinal products (medicines for rare diseases)

▪ Advanced therapies such as gene and cell therapy and tissue engineering products

Bild

: © v

fa / M

artin

Jop

pen

10

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

But they will only do so if the general conditions for venture capital

are significantly improved. The political decision makers seem to

agree on this objective – now all they have to do is adopt relevant

new laws.

The Start-Up Capital is Booming

For many years, the Berlin-Brandenburg region has been gener-

ating international headlines as the start-up capital of Germany.

Hardly a week goes by without a new start-up being founded, a

major financing round being concluded or a major corporation

committing to act as an accelerator or incubator. The region is

booming; it’s an international hot spot. However, this has more to

do with IT and web-based applications start-ups.

Till Erdmann

Managing Director Myelo Therapeutics GmbH

Dirk Pleimes

Managing Director and Chief Medical Officer

Myelo Therapeutics GmbH

We are a young pharmaceutical company that develops new

therapies in fields of application with high medical needs. With

a clear strategy for developing our innovative active ingredient

Myelo001 for treating chemotherapy-induced neutropenia, we

have successfully obtained the support of a series of strategic

investors, including IBB Beteiligungsgesellschaft, Eckert Life

Science Accelerator (ELSA) and Valenta Pharmaceuticals.

The German capital region provides a high concentration of

science and research, clinics and business, as well as a high

quality of life. It is predestined to be a location for pharma-

ceutical companies. The technology parks and networks that

are part of the Healthcare Industries cluster represent an out-

standing infrastructure for translating the latest scientific find-

ings into innovative products.

0

10

20

30

40

50

60

70

80

90

100

110

120

130

140

150

160

170

180

190

200

210

Agriculture/Food

Market Segments of Companies

White Biotechnology /Environmental Biotechnology Biomedicine

'13'04 '05 '06 '09 '10 '11 '12'07 '08 '13'04 '05 '06 '09 '10 '11 '12'07 '08 '13'04 '05 '06 '09 '10 '11 '12'07 '08

Nu

mb

er

of

co

mp

an

ies

3114%

4519%

20488%

Most companies focus on biomedicine. A total of 88 % of companies, focus primarily on development in the areas of new diagnostics, drug development and associated services or technologies. 13 % of the companies are active in the agriculture / food sector, white biotechnology / environmental biotechnology amounts to 19 % of all entries. (Source: Internal survey, BioTOP database, responses from 232 companies, multiple entries, February 2014)

BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin | Germanywww.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11

A AT T G A CAC ACG TTC GCC GAT AAG GAA G T T ATG GAA C C TGGA CCA TCA CGA TAA AAC GGA CAA T TA CCC GAT TGG AAAATC GAA ACC GAA TCA GCC AGT CAA GAA GCT TTC GAC T G CG TA T T G CAA GGC CAC CAG TAG CAC ACG TGC GGA ACG AC ATA A ACT GGA ACA AGA TCC AAA GCT T AT TGG AAG TGC CCGCCA STudieS & ConSulTinG GCA TAC CAA TGC ATG CAC GGAAGG TTC G TA T TA ACT AGA GAT CAT T C T AAC CCT TAT AGC GTT ConferenCeS AAG GAG ATC CCC TTG ACC GGC CGG T T TTCC CTC CTG GCG GTG TCA AAT CAG TGA CGA CCG T G T ACAACA BookSTC TCG CCA TA A CGT TGG C T T AAA GCT TAG GCCGCC ACG GAA ACG GGT GAC GGG A AT CCA ACC GAC AGA AT TTGA TV & VideoAC TCC GCA C AT TTG CGA GCT AGA ACG TA AGCC TAG GCT CAA AAC GCA TG T GCC G AT CAA GAA TGC AAGG AT CorporATe puBliShinG T T T GGA GAA C TA ACA T C T AGAATC CAG C T T ACC AGA TGC AAG AT C T TG GGA GGC AC T GAGG TA inTerneT CTC CGC ACG TCC A AT GGA ATC G TA TA A C C AAGG GTT TCC ACA GCC TGA GCC G AT ATC G TA AGG TGA CAAGAA MAGAzineSGA TTC GTC CTC AGT ACG TCA TAG CAA A C TCAC TC A ACC CAA GGA G T T G TA C TA CTG CGC GAA C T T ACGCGA eVenT MAnAGeMenTTA GCG TCG ACG CAC CAA TGC ACCGCC AAC GCC CAG TCC AT T AGA GAG TCA TA A GAC GCA GCACAA CAC GCT GT T CCC GGA TGC AC A GCC AGG ACT C T T TGCAGC GGC AAA GCA C AT CCA AGA GAA TGG GAC ACG TGC CACACC GGC GCA TG T TGA CAC AAT CAG CCT G AT TAG CAC CAGTA A GC T AGA CAA ACA T C T W e Cre AT e knoWledGe ! TGGAGT G T T CTC AAG GAA TGA CGA TG T GCC T TG ACC TCG ACGG T T ACT ACG TC C TGC ATG T TG CGA T TG GGA AGA AAA C T C

Biocom_A4_mr1.indd 1 05.10.2011 16:22:39 Uhr

12

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

Does this status relate at all to start-ups in the life sciences? At first

glance, perhaps not. But take a closer look: The large number of

players (founders, investors and incubators), the university sup-

port programs and many start-up competitions, and the range of

various activities create a start-up-compatible atmosphere, which

has a positive impact on the start-up scene in the life sciences.

Putting it simply, the spillover effect is high.

There have not been as many life sciences start-ups in years as

there were in the last half of fiscal year 2013/2014. And the strik-

ing thing about them is that some of the new companies are focus-

ing on new drug development. Here are a few examples of recent

start-ups and their concepts:

OMEICOS Therapeutics is a spin-off of the Max Delbrück Cen-

ter for Molecular Medicine. It develops synthetic compounds with

innovative modes of action for the treatment of various human

diseases. The company is working on a new drug for the treat-

ment of atrial fibrillation, the most common type of human car-

diac arrhythmia. Myelo Therapeutics has developed a drug for

the prophylactic treatment of post-chemotherapy patients whose

blood contains too few white blood cells (neutropenia) or platelets

(thrombocytopenia). Venture capital investors IBB Beteiligungs-

gesellschaft with their VC Fonds Technologie Berlin, Eckert Wag-

niskapital und Frühphasenfinanzierung and JSC Valenta Phar-

maceuticals are in the company’s financing consortium. Amal

Therapeutics, a company with facilities in Geneva and Berlin, is

developing a vaccine consisting of a recombinant protein with a

cell-penetrating peptide acting as a vector. The unique property

of this platform is its ability to trigger a highly integrated, multi-epi-

topic cellular immune response to cancer cells. DexLeChem, a

TU Berlin spin-off, provides development services to the chemi-

www.takeda.de

For more than 230 years, Takeda has been serving society with innovative medicines. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Of our 30,000 employees worldwide, 1,700 are working in Germany to develop, produce and market a broad range of medicines to help patients reclaim valuable moments of life from illness.

Our Business: Committed to Improving Health

takeda_A5_1404.indd 1 15.04.14 10:41

13

BioTOPics 47 | May 2014 BioTOP-Report Biotechnology

cal-pharmaceutical industries for making production processes

more chiral, meaning to convert substances with spatially complex

designs into water-based processes. The catalyst is not modified

before re-use. With this resource-conserving reaction process

control, customers – drug and fragrance manufacturers – benefit

from more cost-efficient, environmentally friendly production pro-

cesses. GlycoUniverse is a technology spin-off of the Max Planck

Institute of Colloids and Interfaces. The company specializes in

the automated development and synthetic production of complex

sugars. With GlycoUniverse’s state-of-the-art oligosaccharide

synthesizer GLYCONEER®, the process of synthesizing complex

carbohydrates that formerly took months or years can be complet-

ed in a matter of days or even hours.

The high number of start-ups is the result of a critical mass of

players, activities and initiatives in the start-up area, its well-

developed infrastructure and excellent location factors as

well. These include the seven biotechnology parks that make

affordable laboratories and technical infrastructure available,

and the many scientific institutes that produce highly skilled

specialists. The universities join in with comprehensive spin-off

support programs, some of which are triggered by the federal

government’s “EXIST-Gründungskultur - Die Gründerhochschule”

competition. Pharmaceuticals giant Bayer Healthcare has

also discovered the region’s potential, providing the technical

infrastructure, professional support and expertise of an

established pharmaceuticals company to young companies via

its CoLaborator, opened in May. Another important element is the

many business plan competitions in which founders receive initial

feedback for their business concepts. With 140 events, a network

of over 200 consultants and over 500 business plan submissions

per year, the Berlin-Brandenburg Business Plan Competition is

one of the largest competitions of this type in Germany.

The momentum in the Berlin-Brandenburg region is powerful –

especially at the interface of IT and the life sciences. There are

a variety of names for this new area, including eHealth, itHealth,

dHealth and mHealth. What they all designate is the successful fu-

sion of the two fields, facilitated by web-based applications in the

medical sector. This development is still young, but with its unique

density of IT and life sciences players, the Berlin-Brandenburg

location is particularly suitable for generating new companies.

The first companies have already been founded; take Caterna, an

online school for visual exercises, or NeuroNation, the new digital

brain-jogging platform for example. There are many new compa-

nies in this new field, and in XL Health, it even has a financially

strong investor specialized in digital health.

Financing and Added Value

VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional Development Fund (ERDF).

Venture Capitalfor companies in Berlin

IBB Beteiligungsgesellschaft mbH offers equity financ-

ing for high tech companies in Berlin. For our fund

VC Fonds Technologie Berlin (€52m) we are looking

for investment opportunities in the biotechnology and

medical technology sector.

Our investment approach is based on hands-on invol-

vement and active management support for each

portfolio company, delivered by our highly expe-

rienced investment team. VC Fonds Technologie Berlin

not only provides capital, but also helps execute the

business plan.

Are you interested? Please do not hesitate to contact us.

IBB Beteiligungsgesellschaft mbH

Mrs. Ute Mercker / Mr. Christian Seegers

Bundesallee 210

10719 Berlin / Germany

Phone: +49 (0)30 2125-3201

www.ibb-bet.de

Selected portfolio companies:

14

BioTOPics 47 | May 2014 BioTOP-Report Pharma

Pharma

Attractive Location

The capital region has developed into one of Germany’s most important, attractive centers for the medical and healthcare industries. Based on the significant growth of the pharmaceuticals industry in Berlin, these sectors are the growth engine of the regional industry. Currently, the sectors employ approx. 10,000 people in the German capital region. This means that pharmaceuticals companies account for around one in every 10 jobs in the regional industry – and every 11th employee in the pharmaceuticals sector in German works in Berlin.

Globally active corporations are located along the Spree River:

Bayer Healthcare, Berlin-Chemie, Pfizer Deutschland, Sanofi

Deutschland and since 2011, Takeda. The capital region is also

home to over 20 medium-sized pharmaceuticals companies, in-

cluding several world market leaders.

Above all, the sectors benefit from the capital region’s excellent

scientific environment and clinical research landscape, the prox-

imity to decision-makers in the healthcare system and the ready

availability of well-educated skilled specialists. A steadily growing

number of global players and medium-sized companies are set-

ting up business here or moving their corporate headquarters to

Berlin and the capital region, to take advantage of these location

assets. With over 220 companies, Berlin is also a leading global

location in the biotechnology sector and the pharmaceuticals in-

dustry has created a close, innovative network with these partners.

The Berlin-Brandenburg region has an outstanding position in sev-

eral sectors that the experts certify as having a strong growth

outlook due to their excellence in innovation.

The pharmaceuticals sector's innovative excellence pays doubly

for Berlin-Brandenburg, which is also one of the country's lead-

ing research locations. The partnership between pharmaceuticals

companies, clinics and hospitals and scientific institutions guar-

antees ultra modern patient healthcare of a uniquely high quality,

and the innovations of the pharmaceuticals companies are creat-

ing and securing the jobs of the future for the region.

The current investment and activities of the local pharmaceuti-

cals sector are proof of Berlin's appeal and bear witness to the

companies' commitment to the capital region. Bayer has paid

billions to conclude the takeover of Norwegian cancer treatment

specialists Algeta. Bayer made the move to strengthen its position

in the tumor medication area. The company is also increasing its

commitment to young, innovative technology companies. In May

2014, it launched the CoLaborator incubator program. An incu-

bator model for biotechnology start-ups, CoLaborator was tested

in San Francisco (Mission Bay) two years ago. In the specially

equipped research building, up to 10 innovative biotechnology

companies can now get to work – thanks to Bayer.

Within the next two years, Berlin-Chemie will invest €40 million in

the expansion of its location, continuing to develop its position as

one of the sector's leading employers.

In Berlin, we find an excellent scientific and commercial envi-

ronment. This is an important basis for further investments and

the expansion of our location in the south-east of the city. In

addition required extensions are planned, among others a new

building for the quality control, a new staff canteen, an exten-

sion of the office capacity for the administrative area and the

resulting infrastructural measures in the form of new roads,

paths and parking facilities for our employees.

Dr. Rainer Uppenkamp

CEO Berlin-Chemie AG

Innovation for better health. Our commitment is to bring to patients around the world quality medicines for use in diag nosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with exper tise of innovative partners from science and industry.

The success of this work is evidenced in new med­i­cines­for­areas­with­significant­unmet­medical­need such as oncology, cardiovascular and blood diseases, as well as gynecology and ophthalmology. Our aim is a better quality of life for all.

You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it.

www.bayerhealthcare.comwww.bayerpharma.com

29409011_BHC_Imageanzeige_210x297_mm_RZ_20140311_HiN.indd 1 11.03.14 12:54

16

BioTOPics 47 | May 2014 BioTOP-Report Pharma

The partnership between Sanofi and Charité that began in May

2010 with a focus on the area of stroke research has proven fruit-

ful. The partners have signed an agreement to a second joint

research partnership, this time with a focus on diabetes. The

scientists and clinicians of both parties will also collaborate in a

diabetes alliance in the future. The alliance aims to improve un-

derstanding of the medical requirements and approaches to the

disease of diabetes and, in joint projects, to implement them as

therapies and make them available to patients more quickly.

After the acquisition of Nycomed in 2011, Takeda moved its Ger-

man headquarters to Berlin and took over the Oranienburg-based

production plant. Oranienburg has a long tradition as a location for

pharmaceuticals production. In the past 20 years, the plant there

has expanded continuously. It now has a production capacity of

7.6 billion pills and capsules per year – 98 percent of which are

exported worldwide. The Oranienburg facility is considered one

of the main competence centers within Takeda's global produc-

tion network. Takeda plans to expand the Oranienburg facility's

production capacity within the next few years.

An important new player, Teva Specialty Medicines, has recently

set up business in Berlin. Newly founded Teva Specialty Medi-

cines is Teva Pharmaceuticals' Original Products division in Berlin.

Its primary area of success is neurology. Teva is the leader in

generics in Germany and an expert in innovative brand business.

At a January 2014 press conference in Berlin, Aristo Pharma pre-

sented a new formulation of a proven drug for treating severe and

extreme pain. The special formlulation was designed for targeted

retardation and 24-hour continuous analgesia when taken once a

day. Founded in 2008, the company belongs to a growing group

of German companies headquartered in Berlin.

DR. KADE acquired Takeda’s OTC business for the German mar-

ket in April 2013. With this move, the traditional Berlin company

has added well-known brands to its current OTC portfolio and

made an investment in the future. In conjunction with the expan-

sion of its OTC business, the company has added new employees

in its Berlin and Constance locations.

PharmaMar is a Spanish member of the Zeltia Group, a leader in

the development of anti-tumor drugs of marine origin. PharmaMar

started its activities in Germany in 2007, when the EMA granted

it marketing authorization for Yondelis® in the treatment of soft tis-

sue sarcomas. Two years later, Yondelis® was approved for the

treatment of ovarian cancer. In 2013, the company established

PharmaMar GmbH in Berlin.

These current examples are only an indication of the pharmaceu-

ticals industry activity in Berlin-Brandenburg – but they illustrate

the extent to which the opportunities here are multi-faceted. They

range from close partnerships with regional biotechnology start-

ups and partnerships with science to location expansion and

inward investment. The range of opportunities and the strategic

options they generate make the Berlin-Brandenburg region highly

attractive.

Dr. Hans-Christian Meyer

Site Manager

Takeda Plant Oranienburg

Pharmaceutical development and production has a long tradi-

tion in the area of Berlin-Brandenburg. The roots of our pro-

duction plant in Oranienburg trace back to the 19th century.

Today, our site plays a pivotal role as a competence center for

solid forms such as tablets and capsules within the worldwide

pharmaceutical production network of Takeda. The support

of the Investitionsbank des Landes Brandenburg helps us to

further expand production capabilities, be prepared for future

growth and create new jobs.

Alfonso Casal

CEO

PharmaMar GmbH

Our presence in Germany, the European State Member with

the largest population in the EU and strong research capa-

bilities is an important step in our European expansion. From

our offices in Berlin we coordinate our commercial operations

as well as supporting other corporate activities in Germany.

Berlin as Capital city, with important competence centers for

the treatment of cancer and strong international orientation

represents a very good opportunity for the development of our

activities.

For more information:

BERLIN-CHEMIE AG · Glienicker Weg 125 · 12489 BerlinPhone: +49 30 6707-0 · www.berlin-chemie.de

Modern research, development and manufacturing

of innovative medicines in Berlin-Adlershof – this is

what BERLIN-CHEMIE stands for. Research and

production are based not only on our experience of

over one hundred years but also on our successful

search for new therapeutic pathways and possibili-

ties. The success we have gained around the world

and the growth of BERLIN-CHEMIE are an endorse-

ment of our high standards.

We – for the life

18

BioTOPics 47 | May 2014 BioTOP-Report Glycoscience

Glycoscience

Glyco Research for Innovations in Health Industry

Alongside genome and proteome research, the study of sugars glycoscience, is increasingly gaining importance. As our knowledge about the function of sugar structures in a variety of biological processes grows, the areas of application for glycoscience are also growing and affecting other fields in the Healthcare Industries cluster such as diagnostics, drug development, regenerative medicine and industrial biotechnology. Sugars can develop complex structures, glycans, and can be even bound to proteins – in which case they are called glycoproteins. Glycans are important for a wide variety of biological processes. They control cell-cell communication and the function and stability of proteins, and play an important role in the immune response. Carbohydrate metabolism malfunctions are typically associated with neurodegenerative diseases, infections and cancer.

Exploiting high potential for interdisciplinary technologies

Glycan structures, as molecules expressed due to illness, can

be used as significant diagnostic parameters and can serve as

differentiation markers for regenerative medicine. Glycan-based

molecules can also be used as vaccines e.g. for malaria and HIV.

Glycoscience also contributes to the development of drugs, in-

novative foods and human-compatible biomaterials. When con-

sidering the diverse application fields of glycoscience, it is ap-

parent that the capital region occupies an outstanding position.

Berlin-Brandenburg is a technology leader in the chemical syn-

thesis of glycans, and in glycan analytics it offers international-

ly significant expertise. We also provide excellent conditions for

applications in the fields with high cross-innovation potential. The

region is a leading international location for research and devel-

opment in diagnostics and the implementation of clinical studies

and also has highly productive drug and nutrition research. With

the university hospital Charité Universitätsmedizin Berlin globally

acknowledged medical expertise is also present in the region.

Establishing a glyco hub in the capital region

Research, whether university-related, independent or clinical,

forms the outstanding scientific basis of the region. The Charité

has been honing its expertise in the fields of glycoanalytics and

glycodesign for many years. The director of the Max Planck In-

stitute of Colloids and Interfaces in Potsdam (MPIKG) and inter-

nationally renowned glycoscientist Professor Peter Seeberger

discovered and developed the total synthesis of complex carbo-

hydrates. GlykoUniverse, a spin-off company, will distribute the

completely automated carbohydrate synthesizer. There are other

excellent companies in the region as well. Located in Berlin, Scie-

nion GmbH is distinguished in the field of glycan microarray tech-

nology for molecular diagnostics. Glycotope GmbH is specialized

in optimizing sugar structures of glycoproteins and developing

therapeutic antibodies for cancer cells. In the wake of a strong

growth period in recent years and the acquisition of €55 million

in venture capital, Glycotope now has over 180 employees and

is a world leader in glycobiotechnology. The objective is to turn

Berlin-Brandenburg into a leading international center for glyco-

science research and translation for the development of diagnos-

tic and pharmaceutical products, cell-based therapies and new

materials for medical applications by employing an expansion

strategy. We will also be working to intensify the technology trans-

fer based on regional networks and stabilize the communication

between science and industry.

GlycanForum, the international conference that takes place in Ber-

lin every year, presents the current status and outlook for glycosci-

ence in biomedicine. It is organized with the support of the Center

for Molecular Diagnostics and Bioanalysis (ZMDB) and BioTOP

Berlin-Brandenburg. The most important conference in the world

with regard to glycoscience, GlycanForum is an outstanding open

exchange platform for business, industry and users. With a sub-

theme of "The leading scientists of Asia," the 7th conference in

2013 was focused on the topics of healthcare, material science,

analytics and synthesis.

Dr. Véronique Blanchard

Head of Glycoanalytics working group

at the Institute of Laboratory Medicine,

Clinical Chemistry and Pathobiochemistry,

Charité – Universitätsmedizin Berlin

As a location for glycoscience, the capital region is unique in

Europe. You find the entire spectrum here, from basic research

to manufacturing industry, which creates the ideal conditions

for efficiently translating research innovations to industry and

clinics. At Charité, we are researching the potential of glycan-

based biomarkers in tumor diagnostics and in bioanalytics for

the quality assurance of stem cell preparation, and developing

a glycan microarray platform for diagnostics.

With more than 15 years of experience, Portus Corporate Finance supports technology focused companies in all areas of financing. We base our work on solid know-how, years of experience and reliable business partners.

If you are looking for advise and support in the areas of• Company and Project Funding• Company Succession / M&A• Finance Management / CFO-Services • Consulting and Coaching• Establishment of Businessesplease don‘t hesitate to contact us!

Corporate Finance Consulting for Life Science Companies

www.PortusCo.com

Portus Corporate Finance GmbHFriedrichstr. 81D-10117 BerlinTel (030) 700 800 900Fax (030) 700 800 901Email info@PortusCo.com

With more than 15 years of experience, Portus Corporate Finance supports technology focused companies in all areas of financing. We base our work on solid know-how, years of experience and reliable business partners.

If you are looking for advise and support in the areas of• Company and Project Funding• Company Succession / M&A• Finance Management / CFO-Services • Consulting and Coaching• Establishment of Businessesplease don‘t hesitate to contact us!

Corporate Finance Consulting for Life Science Companies

www.PortusCo.com

Portus Corporate Finance GmbHFriedrichstr. 81D-10117 BerlinTel (030) 700 800 900Fax (030) 700 800 901Email info@PortusCo.com

We have offices in Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart

For further information please contact Dr. Ulla PetersUHY Deutschland AG · Wirtschaftsprüfungsgesellschaft · Zimmerstraße 23 · 10969 BerlinPhone +49 30 226593-0 · Fax +49 30 22679050 · www.uhy-deutschland.de · www.uhy.com

UHY Deutschland AG is a joint venture of long established auditing and consulting firms with a total of 250 employees and partners.

As a member of UHY International, a global association of independent accounting and consulting firms with over 7,600 employees, we can provide audit, accounting, tax and consulting services in 275 business centres across the globe.

UHY Deutschland AG has extensive experience in financial and consulting services for life sciences companies for many years.

We offer the following services:

• Audits of financial and consolidated statements under the German Commercial Code (HGB) and IFRS

• Accounting & Reporting • Due diligence (financial and tax) and business valuations • Consulting services on IPOs • Business Advisory • Mergers & Acquisitions (M&A) • German and international taxation

20

BioTOPics 47 | May 2014 BioTOP-Report Bioelectronics

Bioelectronics

The Joint Lab Bioelectronics – A New Platform for the Integration of Microelectronics into Life Sciences

The introduction of new experimental techniques causes a major advantage in the field of biology. Well-known examples are the invention of optical and electron microscopy, without which the fundamental structures of life as cells and cell organelles could not have been discovered. The next paradigm shift may very well be triggered by applying microelectronics – and its developing field of bioelectronics – at its interdisciplinary interface with the life sciences.

This positive outlook is mainly a result of the phenomenon called

“scaling” in microelectronics: for the last few decades, minimum

feature dimensions have continuously become smaller by a fac-

tor of around two every second year. At first glance, this seems

to be a minor development relating to an uninteresting technical

parameter, since we have become accustomed to working with

increasingly powerful computers and to storing higher and higher

data volumes on a single flash memory. For the life sciences, how-

ever, scaling is a major advance. It has taken microelectronics or

more accurately, nanoelectronics, to the same structural levels at

which the molecular mechanisms of life operate.

Particularly interesting perspectives arise for biosensorics, in

which semiconductor preparation technology can be applied to

the fabrication of cost-effective diagnostic systems. Bioelectron-

ics is also significant for the process analytical techniques (PAT)

for monitoring, regulating and increasing the efficiency of biopro-

cesses. The Berlin-Brandenburg region is eager to take advan-

tage of this development and therefore, IHP in Frankfurt (Oder)

and the TU Berlin Institute of Biotechnology have founded Joint

Lab Bioelectronics. This step will intensify the interdisciplinary ex-

change between the two disciplines and expand biotechnology

students’ knowledge of the basics of microelectronics.

JANUARY 2013Charité and FU are jointly successful in the competition "EXIST-Gründungskultur – Die Gründerhochschule" of the German Federal Ministry of Economics and Technology +++ German Research Foundation extends collaborative research centre (SBF 650) at Charité – ten million Euros for research on immunological therapy

FEBRUARY 2013Humboldt research award gets Ivy-League professor Klaas van Wijk to Potsdam +++ Biopolymers – strong future field with high potential for innovation presents itself in Schorfheide

MARCH 2013Hasso-Plattner-Institut speeds up personalised medicine with new data bank technology +++ Integrative Research Institute for Life Sciences (IRI) founded in Berlin +++ Paul Ehrlich- and Ludwig Darmstaedter Prize goes to MDC scientist Dr. James Poulet

APRIL 2013Charité and Sorbonne found Virchow-Villermé Centre for Public Health +++ EU-OPENSCREEN included in the new BMBF-roadmap for large research infrastruc-tures

MAY 2013New laboratory building of MDC opened – named after physiologist Max Rubner +++ Stem cell researchers in Germany pool their expertise. They found the Ger-man Stem Cell Network (GSCN) on May 7th 2013 +++ Evaluators praise Berlin Institute of Health (BIH). Enst Theodor Rietschel becomes chairman

JUNE 13BIH officially opened +++ Charité – Universitätsmedizin Berlin once more reach-es rank 1 of Focus-ranking "Germany's best hospital"

JULY 2013Prof. Angelika Eggert receives Einstein professorship and takes over as head of the Children's Clinic with focal areas of oncology and hematology +++ Scien-tists from the A*STAR Genome Institute Singapore and the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin decode the communication network in human embryonic stem cells +++ Scientists from Charité and the MDC, working in cooperation with colleagues in Kiel, Boston, Zurich and London, discover a new gene for hereditary heart failure +++ Scientists working with Peter Seeberger (MPIKG) in Potsdam-Golm have developed a simple, cheap and reliable test for Yersinia pestis, the bacteria that caused the plague

AUGUST 20131000th protein structure decoded at BESSY II +++ The World Health Summit 2013 in Berlin in August 2013 discussed solutions for global healthcare with regard to

“Research and Innovation.” +++ BPI and vfa present national plans of action for the quick diagnosis and more effective treatment of rare diseases

SEPTEMBER 2013Scientists at Charité and MDC discover sugar withdrawal as an innovative cancer therapy approach +++ Technische Universität Berlin and Leibniz Institute IHP Frankfurt (Oder) have established Joint Lab Bioelectronics, a laboratory for joint interdisciplinary research +++ Charité and Harvard sign a cooperation agree-ment aimed at accelerating clinical translation, primarily in the cell and tissue technology field +++ Prof. Annette Grüters-Kieslich, Charité Dean, receives the

Prof. Dr. Peter Neubauer

Technische Universität Berlin

Institute for Biotechnology

Chair for Bioprocess Engineering

The Joint Lab Bioelectronics aims to advance the field of Bio-

Process Analytical Technologies by connecting sensor spe-

cialists and bioengineers.

21

BioTOPics 47 | May 2014 BioTOP-Report Bioelectronics

The Leibniz Institute IHP – Innovations for High Performance

Micro electronics – in Frankfurt (Oder) is part of the Leibniz

Association and has a long tradition in the area of silicon-based

microelectronics. The IHP has a clean room at its disposal for the

pilot serial production of 200-mm Si wafers in which microchips

are processed at the 0.25 and 0.13 µm structure levels. A family of

SiGe: C-based hetero bipolar transistors for realizing frequencies

in the low 100 GHz range is the core of IHP technology. As part

of IHP’s multi-project wafer services, external customers may use

the technology for the fabrication of application-specific integrat-

ed circuits.

The TU Bioprocess Engineering chair conducts research on the

characterization of industrial-scale bioprocesses and methods for

consistent, faster bioprocess development. The chair runs a bio-

process pilot plant with advanced analytical instruments, on-line

instrumentation and an analytical laboratory for comprehensive

metabolomics analysis. Its key instruments are proprietary, scale-

down two- and three-compartment bioreactors, which enable the

simulation of large-scale industrial processes in the lab. The char-

acterization of biogas plants, brewery reactors and reactors in

industrial biotechnology with new PAT and model-based process

control for improving their robustness are a major focus. For this

highest honor offered by ESPE, the European Society for Paediatric Endocrinol-ogy: the Andrea Prader Award +++ New Helmholtz post-graduate school for researching biomaterials opens

OCTOBER 2013Fraunhofer researchers receive an international award for ArtCornea®, their artificial cornea +++ The capital has healthcare in focus: Berlin Health Week celebrates its launch +++ Sanofi endows two new professorships in the public health field at Centre Virchow-Villermé, the newly established German-French research institute, in its Berlin and Paris locations +++ Charité opens the inten-sive care station of the future

NOVEMBER 2013NeuroProAllianz receives Technical University of Applied Sciences Wildau research award Dr. Jean-Yves +++ K. Tano from the University of Toledo arrives in Berlin after receiving an Alexander von Humboldt fellowship +++ Charité coordinates the national network of biobanks +++ Immunologist Prof. Klaus Rajewsky from MDC Berlin awarded the Society for Signal Transduction medal of honor

DECEMBER 2013Charité opens pioneering robotics operating room +++ Scientists from Charité present new approaches toward improving breast cancer therapy as part of the RESPONSIFY EU research project

JANUARY 2014Under the leadership of Cornelia Weikert from the German Institute of Human Nutrition (DIfE), a team of scientists has discovered a new biomarker for heart

failure in the general population +++ Researchers at MDC Berlin have acquired new knowledge of the body's regulation of insulin production for insulin resis-tance, the root of type 2 diabetes +++ The biochemist and protein crystallogra-pher Prof. Oliver Daumke from MDC Berlin-Buch receives European Research Council funding worth millions +++ BTU Cottbus-Senftenberg strengthens bio-materials research network with Helmholtz Center Geesthacht in Teltow

FEBRUARY 2014MPIKGPotsdam director Prof. Peter Seeberger and the director of the NII in New Dehli, India agree to intensify their partnership for researching infec-tious diseases +++ Researchers at MDC decipher the creation of new forms of hereditary Alzheimer’s disease and discover new protective mechanisms +++ Researchers at the Max Planck Institute for Moldcular Plant Physiology in Potsdam-Golm discover new adapter proteins for the reception of substances in plant cellss +++ The Berlin Institute of Health (BIG) acquires Thomas Südhof, Noble Prize for medicine co-awardee, as visiting fellow

MARCH 2014Two dozen Fraunhofer Society institutes establish the Big Data Alliance +++ MDC receives 3-Tesla MRI scanner for the largest long-term German popula-tion study +++ MDC researchers discover the molecular switch for epilepsy

APRIL 2014Berlin Institute for Health Research launches first research projects +++ Hans-Hilger Ropers awarded with the “EURORDIS Scientific Award 2014” for his research on rare diseases

PD Dr. Mario Birkholz

Head of Joint Lab Bioelectronics

IHP GmbH

Leibniz-Institut für innovative Mikroelektronik

By establishing the IHP and TUB Joint Lab Bioelectronics, we

have created the opportunity for a successful interdisciplinary

partnership. Through it, we will be able to translate the prog-

ress made in microelectronics directly into biotechnological

applications and university education.

22

BioTOPics 47 | May 2014 BioTOP-Report Bioelectronics

purpose, new lance- and rope-based mobile sensor and sam-

pling systems that can be directly applied to analyze concentra-

tion gradients have been developed.

A robot-based mini pilot plant has also been established for pro-

cess development in micro-plate and mini-bioreactor cultures.

This highly automated facility focuses on processes with genet-

ically engineered microorganisms. Extensive analyses are au-

tomatically performed on tens to hundreds of cultivations in μl

and ml formats. The laboratory pioneered the EnBase® controlled

substrate delivery technology, which is instrumental for consistent

bioprocess development and a key element in this high-through-

put (HT) automated industrial reference laboratory.

Joint Lab Bioelectronics’ mission is to introduce new biosensor

technologies. This work focuses on the adaption of the sensor

system to the particular biotech application. The starting point is

the sensor chips developed at IHP, including a fully embedded

microelectromechanical system (MEMS) for affinity assays and a

cell sensor operated via impedance spectroscopy (see Fig. 1).

However, the biochips fabricated in semiconductor fabs require

special packaging before being introduced into bioprocesses

with an emphasis on hermiticity and must be shielded against

corrosion from the liquid bio milieu.

The demand for microsensors for applications in microfluidic

platforms has jumped in recent years. Many applications rely on

polymer devices, because most companies and scientific work-

ing groups have almost no access to microelectronic fabrication

techniques. Joint Lab Bioelectronics follows the approach of de-

veloping and supplying biotechnological platform modules that

combine equal shares of microelectronic and microfluidic com-

ponents.

Bioprocess engineering is one promising field of application for

miniaturized sensors. Industrial bioprocess development faces

the challenge of reducing the risks, costs and timeframe of new

product launch. In the pharmaceuticals industry in particular, the

regulatory authorities expect dossiers to be based on knowledge

that derives from careful sensing (PAT). Consequently, future bi-

oprocess development will consist of HT technologies based on

miniaturizing, parallelization, automation and intense monitoring.

Joint Lab Bioelectronics is a perfect match for the Bioprocess

Engineering chair’s HT lab, where platform technologies are de-

veloped to comply with the above-mentioned needs. This lab is

Figure 1. Affinity-viscosimetric microsensor chip with fully embedded MEMS (X-shaped beams on the left) und calibration curves for glucose concentration measurements it has taken, Birkholz et al., J. Appl. Phys. 113 (2013) 244904.

glucose concentration cg (mM)

T dependence of tswin sensoric fluid

for varying cg

150

140

130

120

110

100

90

80

switc

hing

tim

e t sw

(m

s)

40º

35º

30º

Figure 2. Steps in consistent, automated bioprocess development based on process analytical technologies, experimental design approaches and the early consideration of the industrial process by applying the fed-batch mode.

Joint Lab Bioelectronics – miniaturized sensors

EnBase®

Fed-batched in μl and mL scale

Robotics

Automatedcultivation

MagReSynTM

Automated DSPand analytics

DoE

Experimental plans, modelling

Sensors

On-linedata reading

Integration

Automateddata evaluation

Achieve innovation, shape the future

High Tech Gruenderfonds is your partner for Seed Stage investing. We

help out young, high potential startups in the early phases of technology

and product development, as well as successful launching. Our assistance

is not limited to our cash investments, instead we strive to add long term

added-value to portfolio companies through our extensive network of

professional and our accredited coaches.

Start shot for young technology companies

Energy

Automation

Photonics

Industrial Software

Software

Internet & Telecommunication

Media & E-commerce Life Science

Materials Science

Nanotechnology & Chemistry

I N V E S T O R S O F H I G H - T E C H G R U E N D E R F O N D S I I

High-Tech Gründerfonds Management GmbH

Schlegelstraße 2 | 53113 Bonn

Phone: +49 (0)228-823001-00 | Fax: +49 (0)228-823000-50

E-Mail: info@htgf.de

ht tp: // www.high-tech-gruenderfonds.de

23

BioTOPics 47 | May 2014 BioTOP-Report Bioelectronics

able to screen volumes of as little as 200 µl per vessel, in up

to 96 vessels at the same time. Process development and pro-

duction process characterization take place simultaneously, in up

to 48 miniaturized stirred-tank bioreactors with a working volume

of approx. 10 ml. The cultivation, process analytics and product

recovery processes are automated with the help of a liquid han-

dling system (lab robot). In close collaboration with Joint Lab Bio-

electronics, the scientists explore the application and integration

of microsensors for glucose concentration and cell density in HT

systems. The overall process development approach relies on

consistency: experimental planning determines parameter fields,

production systems are investigated under process-related con-

ditions and IT tools handle data. These platform technologies are

currently being applied to specific demonstrator processes. Inter-

ested customers can also take advantage of the HT lab’s services.

Last but not least, Joint Lab Bioelectronics aims to teach micro-

electronics to Biotechnology students, since the job markets of

the the future will demand large numbers of graduates special-

ized in this field. The “Introduction to Bioelectronics” course was

introduced in 2012 and has been held every summer semester

since then. It was recently included as a mandatory elective

course in the Master of Biotechnology program at TU Berlin.

For the second year in a row, Joint Lab Bioelectronics will organize

a bioelectronics symposium in September 2014, where leading

experts in the field will discuss their recent developments. IHP will

present its biotechnology-relevant technology modules during the

second day of the symposium. We cordially invite interested col-

leagues from the life sciences and microelectronics to participate

in the symposium.

Achieve innovation, shape the future

High Tech Gruenderfonds is your partner for Seed Stage investing. We

help out young, high potential startups in the early phases of technology

and product development, as well as successful launching. Our assistance

is not limited to our cash investments, instead we strive to add long term

added-value to portfolio companies through our extensive network of

professional and our accredited coaches.

Start shot for young technology companies

Energy

Automation

Photonics

Industrial Software

Software

Internet & Telecommunication

Media & E-commerce Life Science

Materials Science

Nanotechnology & Chemistry

I N V E S T O R S O F H I G H - T E C H G R U E N D E R F O N D S I I

High-Tech Gründerfonds Management GmbH

Schlegelstraße 2 | 53113 Bonn

Phone: +49 (0)228-823001-00 | Fax: +49 (0)228-823000-50

E-Mail: info@htgf.de

ht tp: // www.high-tech-gruenderfonds.de

24

BioTOPics 47 | 6. Juni 2014 (3:02) BioTOP-Report Business Location

Business Location

Excellent Services for Berlin-Brandenburg

The Berlin-Brandenburg region harbors outstanding potential for technological development and cooperation in its high-density landscape of scientific and research institutions. The high concentration of international excellence here facilitates interdisciplinary exchange, making it easier to realize new, landmark developments. At the same time, the sheer number of players can make it difficult to find the right partner. The region’s Inward Investment and Expansion team supports the healthcare and life sciences sectors with a full range of services, including marketing activities at national and international trade shows. Our team has been in direct contact with the region’s companies and scientific institutions for many years and can provide quick access to the right contacts and potential partners.

In 2013, Berlin Partner for Business and Technology supported

expansion projects and provided location services to 33 compa-

nies in Berlin, generating around 320 new jobs and a projected

investment of €63.9 million within the next three years. The list of

companies includes Cell Medica, CBR Biotech Strategies, Amal

Therapeutics and G&Life, an Italian company.

In the same year, the Brandenburg Economic Development Board

(ZAB) supported approx. 130 investment and innovation projects

in the healthcare sector with a total investment volume of around

€27 m and the potential to create 220 new jobs. The successful

location of technology-based start-ups such as Glyco Universe,

ai-ibiomics and medneo deserves special mention. The team

at ZAB also supported the expansion investments of resident

companies co.don and Seramun. With the aim of positioning

the region’s companies in the global markets and presenting the

Berlin-Brandenburg Healthcare Industries cluster – HealthCapi-

tal – as one of Europe‘s leading healthcare sector locations, the

region exhibited at four important international fairs in 2013.

As in previous years, we organized a Berlin-Brandenburg Night

to mark the opening day of the BIO conference and exhibition

in Chicago. Once again, Bayer HealthCare was the lead sponsor.

Accepting the invitation from HealthCapital and Bayer HealthCare,

around 400 international guests from biotechnology and pharma-

ceutical companies attended the event.

To provide support in the areas of internationalisation, technology

transfer and regulatory affairs to companies and scientific institutes

already located in Berlin and Brandenburg, we organized more

than 30 conferences, workshops and networking events last year.

The 2,000 accredited participants came from all over Germany.

Berlin-Brandenburg is also a life sciences hot spot for internation-

al delegations. At the 2013 BIONNALE, our annual biotechnology

conference, a group from Denmark presented its products and

services and networked with representatives from regional com-

panies and scientific institutions.

In 2013, we kicked off the first “Health Week” for the capital re-

gion. Companies and organisations from the healthcare industries

took advantage of the opportunity to showcase their prevention,

diagnostics and therapy expertise and services. Over 90 com-

panies and institutions organized more than 300 public events in

one week.Dr. Rainer Knaus

Senior Vice President

Cell Medica Ltd.

Cell Medica, a leading T-cell therapeutics company and pio-

neer in the field, acknowledges the importance of the Ger-

man market and especially the excellent conditions in Berlin.

The European commercial manufacturing facility within the

Campus Berlin-Buch biotechnology park was designed and

equipped to facilitate the high quality GMP-compliant produc-

tion of patient-specific cell therapies for distribution across

Europe. Here in Berlin, we have found an outstanding scien-

tific and industrial environment that allows us to attract highly

educated, well-trained personnel who are keen to help shape

this new era of cell-based therapeutics.

Carolin Clement

Head of Unit Biotech I Pharma

Berlin Partner for Business and Technology

Phone +49 30 46302-430

carolin.clement@berlin-partner.de

www.berlin-partner.de

Dr. Ute Hartmann

Head of Department Healthcare Industry/ Life Sciences

Brandenburg Economic Development Board (ZAB)

Phone +49 331 20029-250

ute.hartmann@zab-brandenburg.de

www.zab-brandenburg.de

Life Sciences. Living Research. Berlin. Brandenburg.

A vibrant network.Berlin-Brandenburg is one of Europe´s leading locations for the Life Sciences. It is also an R&D capital that magnetically attracts the world´s top scientists. Here you´ll find attractive funding conditions, close linkages between business and science, the highest concentration of R&D in Europe, a dynamic startup scene and a multifaceted entrepreneurial environment made up of more than 500 pharmaceutical, biotech and medical technology companies. Come discover this one-of-a-kind landscape for scientists and entrepreneurs.

www.healthcapital.de

210x297_BIOTOP_Motiv_LifeScience_eng.indd 1 17.04.2014 15:35:53

26

BioTOPics 47 | May 2014 BioTOP-Report Spotlight on European Business and Internationalization

Spotlight on European Business and Internationalization

The Enterprise Europe Network Berlin-Brandenburg

The Healthcare Industries cluster Berlin-Brandenburg has been an active member in a variety of European networks and initiatives for many years. With the launch of Horizon 2020, the new EU research funding program, one network in particular has taken center stage: the Enterprise Europe Network (EEN) Berlin-Brandenburg. With 20 experts on Europe from the three participating host organizations Berlin Partner for Business and Technology, Brandenburg Economic Development Board (ZAB) and the East Brandenburg Chamber of Commerce and Industry, it is the basis for internationalization in the region – primarily for small and medium-sized companies.

Helping SMEs find business and technology partners throughout

Europe, the EEN provides information and advice on the innova-

tion-oriented developments, initiatives and programs of the Eu-

ropean Union. The EU Commission initiated the network, which

connects 100 regional consortia in approx. 60 countries in Europe

and the world to each other, at the beginning of 2008. Over 500

regional economic development institutions, chambers of indus-

try and commerce and technology agencies with a total of 4,000

employees collaborate closely within the network. Supporting

small business is a cornerstone of the EU's drive for growth and

jobs: 99% of all companies in the EU are small and medium-sized

(SMEs) and they account for 67% of the jobs. The EEN’s services

are tailored to SMEs, but are also available to all other businesses,

universities and research centers.

Services tailored to small companies

Taking part in an EU-funded research project is a great way to

boost a company's competitiveness. SMEs need the right partners

for successful projects, and the Enterprise Europe Network helps

by identifying companies' needs and potential and connecting

them with each other. The network does not fund any projects itself,

but helps companies to tap into the EU's funding opportunities.

Horizon 2020 leads the way – it is the EU's latest research funding

program, launched in December 2013 with a volume of almost

€80 billion. Normally, its consortia must consist of companies from

three different EU countries, but the EEN also assists SMEs with

this aspect. The network’s business cooperation database is one

of the world's largest and contains thousands of company pro-

files. Companies can meet potential business partners in person

at EEN’s matchmaking events, which often take place at interna-

tional fairs to help keep travel and accommodation costs low.

For example, the Enterprise Europe Network Berlin-Brandenburg

played a major role in opening up the annual BIONNALE – the key

biotechnology and pharmaceutical industry meeting place in the

capital region – to an international audience. Almost 80 partici-

pants, including a larger company delegation from partner coun-

try Denmark, gathered for the matchmaking event EEN organized

in 2013. On the day of BIONNALE 2013, the participants held

around 160 meetings.

The regional EEN contact point for all themes relating to the

healthcare industries:

Wolfgang Korek

Project manager EEN Healthcare Industries

Phone +49 30 46302-518

wolfgang.korek@berlin-partner.de

www.berlin-partner.de

Dajana Pefestorff

Project manager International Business

Director EEN

Phone +49 331 660-3234

dajana.pefestorff@zab-brandenburg.de

www.zab-brandenburg.de

Elias Zafirakos

Science & Innovation Network Manager

Biopeople Københavns Universitet

The matchmaking session organized by the Enterprise Europe

Network gave the Danish delegation a valuable opportunity

to meet with potential German collaboration partners at the

Bionnale 2013. The EEN setup made it possible to plan and

book meeting ahead of the conference and was a great help in

exposing the Danish Delegation towards the German audience.

27

BioTOPics 47 | May 2014 BioTOP-Report 2014

Alacris Theranostics GmbH Alacris Theranostics GmbH is a Berlin-based

company with the mission to exploit next gen-

eration sequencing and other omics data

through its predictive modelling system Mod-

CellTM for drug development and person-

alised medicine in oncology. This approach

was originally developed at the Max Planck

Institute for Molecular Genetics in Berlin and

is exclusively licensed to Alacris.

Alacris provides extensive bioinformatics

expertise and well equipped facilities includ-

ing a next generation sequencing lab for

clinical application and a powerful IT infra-

structure. Alacris works together with clinics

and industry leaders in the fields of person-

alised medicine, biomarker application, and

drug development.

With its proprietary ModCell™ System,

Alacris Theranostics applies a new, revolu-

tionary systems biology modelling approach

to better match patients to therapies and

therapies to patients. ModCell™ provides a

'Virtual Patient' model allowing predictive

analysis of cancer patient samples on thera-

py outcome. ModCell™ integrates next gen-

eration sequencing derived genome and

transcriptome information with a generic can-

cer model of molecular processes in tumour

onset and progression. ModCell™ facilitates

the simulation of the effects of different

drugs for the development of new personal-

ized medicine approaches in the clinic and

for effective development and approval of

drugs for the pharmaceutical industry in 'Vir-

tual Clinical Trials'.

Address

Alacris Theranostics GmbH

Fabeckstraße 60-62

Phone +49 30 84312250

14195 Berlin · Germany

info@alacris.de

www.alacris.de

Unlocking The Power OfIndividualised Medicine

co.don AGThe biopharmaceutical company based near

Berlin is one of the leading specialists world-

wide in cell cultivation for the regenerative

treatment of articular cartilage defects and

spinal disc defects. In many cases the use of

the company's patented pharmaceutical

product can avert the need for joint and spi-

nal disc replacement surgery. Orthopaedic,

accident and neuro-surgeons are increas-

ingly applying these regenerative treatment

methods. co.don® AG manufactures cell-

based tissue engineering therapeutics to the

highest quality standards. Its products repre-

sent a revolutionary pro cess in the biological

replacement of dam aged articular cartilage

and invertebral disc by building up strictly

autologous tis sue without the involvement of

any external carrier materials or additives.

The applica tion of the products may be mini-

mally inva sive or arthroscopic and so surgery

and reha bilitation times are significantly

reduced for both doc tor and patient. Because

no external materi als are used, the risks of

rejection, inflamma tion and infection are

reduced to the minimum. co.don® AG is certi-

fied in accordance with DIN EN ISO

9001:2008. Furthermore, pro duction, quality

control and quality assur ance have been cer-

tified in accordance with European Guide-

lines for Good Manufactur ing Practice (EU-

GMP). co.don® AG‘s technological, produc-

tion and regulatory expertise makes the com-

pany a first mover in the market for biological

carti lage and disc tissue replacement and a

provider of highly effective, safe treatment

options not only resulting in relief of pain, but

actual repair of damaged tissue.

co.don® AG is listed on the Frankfurt Stock

Exchange (ISIN: DE000A1K0227).

Address

co.don AG

Warthestraße21

14513 Teltow · Germany

Contact

Matthias Meißner, M.A.

Head Corporate Communications/IR/PR

Phone +49 3328 4346 0

Fax +49 3328 4346 43

info@codon.de · www.codon.de

28

BioTOPics 47 | May 2014 BioTOP-Report 2014

Evestra GmbHEvestra GmbH, founded in July 2008, is a

fully owned subsidiary of Evestra Inc. located

in San Antonio Texas. Evestra GmbH serves

as the development and commercialization

center for Europe and ROW. Evestra’s mis-

sion is to develop and commercialize steroid-

based female healthcare products. The

development strategy of the company

includes product ideas with known com-

pounds as well as New Chemical Entities.

Evestra is conducting research and product

development in a number of in-demand, but

as yet unmet, medical need areas of wom-

en’s health such as hormonal-dependent

breast cancer and endometriosis. The com-

pany is also pursuing different projects in

fertility control, e.g. a new estrogen for oral

contraception, with superior pharmacologi-

cal properties compared to the standard

drug ethinyl estradiol.

Several patents on new composition of mat-

ter, new technical processes and use patents

have been filed during the last years and

support the strong intellectually property

position. Evestra is concentrating on R&D

and will seek more partners for commercial-

ization.

More detailed information can be found on

our website.

Address

Evestra GmbH

Britzer Straße 26

12439 Berlin · Germany

EU Contact

Prof. Klaus Nickisch · Managing Director

Phone +49 30 66509642

knickisch@evestra.com

www.evestra.com

LGC GenomicsAt LGC we offer a full range of high quality

PCR reagents, custom genotyping assays,

genomic services and workflow solutions for

DNA sample preparation and downstream

processing (www.lgcgroup.com/genomics).

Our proprietary KASP™ allelic discrimination

chemistry and has optimised workflows for

1536 microtitre plates that enable assay min-

iaturisation for more flexible, cost-effective

workflow solutions in high-throughput geno-

typing. In addition, customers are offered

industry leading proprietary nucleic acid

extraction, sequencing and genotyping ser-

vices from our labs globally.

„We use what we sell and sell what we use”

is key to the products and services we pro-

vide.

Our portfolio includes:

k Genotyping services, assays and

reagents

k Sanger and next-generation sequencing

services

k DNA and RNA extraction products and

services

k PCR reagents and consumables

k Laboratory instrumentation

k Plate sealers

k Liquid handling robots

k High-throughput PCR thermal cyclers

k Plate readers

We operate sales offices in the UK, Germany

and the USA, with sales representatives

throughout Europe, the USA and Australia as

well as distributors in China, Korea and other

key emerging territories.

Address

LGC Genomics GmbH

Ostendstrasse 25 · TGS Haus 8

12459 Berlin · Germany

Phone +49 30 53042200

genomics@lgcgroup.com

www.lgcgroup.com/genomics

29

BioTOPics 47 | May 2014 BioTOP-Report 2014

Metanomics Health GmbH

Metanomics Health – a BASF Group compa-

ny – combines comprehensive Metabolite

Profiling (metabolomics) with biomedical

data interpretation. Metabolite Profiling is

defined as the parallel analysis of multiple

endogenous and xenobiotic metabolites in

biological systems. The core expertise of

Metanomics Health resides in discovery and

validation of biomarkers.

Technologies

k Metabolite profiling platform with more

than 75 GC-MS and LC-MS/MS instru-

ments

k Wide metabolite coverage via combina-

tion of unbiased and targeted platforms

k Unique tox mode of action prediction

through MetaMap®Tox database

k Excellence in systems correlation analy-

sis of complex gene function relation-

ships

k Highly robust and reproducible results

Major R&D-Topics

In cooperation with academic institutes and

clinical experts Metanomics Health is run-

ning a large-scale diagnostic biomarker pro-

gram. Areas include metabolic syndrome,

heart failure, prostate cancer and pancreatic

cancer to mention a few.

Market Segments

Metanomics Health provides its services to

pharmaceutical, diagnostics and nutrition

companies. Technology applications include:

k Mechanism of action studies

k Mechanism of toxicity studies

k Translational and clinical biomarker

development (e.g. PK/PD, patient stratifi-

cation, efficacy and safety markers)

k Companion diagnostic development

k Cell culture & bioprocess optimization

k Biospecimen quality control

Address

Metanomics Health GmbH

Tegeler Weg 33 · 10589 Berlin · Germany

Contact

Dr. Tim Bölke · Managing Director

Phone +49 30 34807 400

Fax +49 30 34807 401

company.info@metanomics-health.de

www.metanomics-health.de

nanoPET Pharma GmbHnanoPET is a biopharmaceutical company

specialized on R&D, manufacturing and mar-

keting of innovative drug substances for

Diagnostic Imaging. We focus on relevant

cardiovascular, oncological and neurological

indications as well as on regenerative medi-

cine. Nanotechnology is a key element of our

business. We operate in three major areas.

The first nanoparticular tracers for clinical

PET: nanoPET prepares the clinical develop-

ment of its patented technology platform:

inorganic nanoparticular tracers for cell- and

molecular-specific positron emission tomog-

raphy (PET).

Viscover™ imaging agents – a landmark in

small animal imaging: As animal imaging is

rapidly gaining relevance in pharmaceutical

research, we are delighted to offer you an

exciting portfolio of specialized pre-clinical

imaging agents covering the principal imag-

ing modalities (MRI, CT, Ultrasound, Optical

Imaging, SPECT & PET). Get a detailed

insight into our product portfolio and down-

load a free copy of our imaging guide on

www.viscover.com

Consulting and Service tailored to your

needs: As a technology and service provider,

we offer our expertise to biopharmaceutical

companies and imaging equipment manu-

facturers. Our customers benefit from the

long-standing industry expertise our team

has attained in the pharmaceutical

research & development.

Address

nanoPET Pharma GmbH

Robert-Koch-Platz 4

10115 Berlin · Germany

Contact

Dr. Andreas Briel · CEO

Phone +49 30 890 49740

imaging@nanopet-pharma.com

www.nanopet-pharma.com

30

BioTOPics 47 | May 2014 BioTOP-Report 2014

ORGANOBALANCE GmbHExploring and managing microbial biodiversity

ORGANOBALANCE explores the potential of

probiotic bacteria and yeasts for new prod-

uct developments in food, feed, personal

care, and for the pharmaceutical industry or

the production of fine chemicals. From a

large collection of microorganisms, specific

strains are selected to e.g. inactivate patho-

gens, produce new bioactives, neutralize

malodorous or toxic substances and synthe-

size high titers of valuable compounds.

ORGANOBALANCE draws on natural

resources, which are gathered in the compa-

ny-owned collection of 8000+ microbial

strains, mostly originating from foodstuffs.

ORGANOBALANCE uses its OASSYS® bioas-

says for highly efficient screenings. The plat-

form allows to quickly identify the most suit-

able strains from the microbial collection for

targeted applications.

ORGANOBALANCE has a broad expertise in

the field of yeast metabolic engineering. This

includes designing and developing new pro-

duction strains for industrial biotechnology

applications. Specific strains of Saccharomy-

ces cerevisiae, which carry engineered bio-

synthesis pathways for the environmentally

friendly production of carboxylic acids, ter-

penoids, steroids and other lipid compounds

are available.

ORGANOBALANCE works in collaboration

with partners and grants licenses for own

product developments.

Address

ORGANOBALANCE GmbH

Gustav-Meyer-Allee 25

13355 Berlin · Germany

Contact

Dr. Christine Lang · CEO

Phone +49 30 46307200

Fax +49 30 46307210

info@organobalance.com

www.organobalance.com

Contact us: Phone: +49 (0)30 / 2125-4747 E-mail: wachsen@ibb.dewww.ibb.de/wachsen

Our tailored fi nancing are your key to success. Our consultants look forward to meeting you.

Getting your innovation going.

140305_IBBanz_biotop12_210x148.indd 1 05.03.14 12:22

31

BioTOPics 47 | May 2014 BioTOP-Report 2014

syneed medidata GmbHAre you getting the whole picture? We Do.

syneed medidata GmbH is an independent,

privately owned contract research organiza-

tion (CRO) providing end-to-end services for

phase I to phase IV clinical trials and for non-

interventional studies. Commencing busi-

ness in 1985, we have constantly expanded

our service portfolio. In 1995 we conducted

our first medical device study, and in the

same year we started our Imaging Core Lab

operations (see below). Moreover, we offer

the complete scope of Pharmacovigilance

services for development projects as well as

for marketed products (drugs and medical

devices). Our notion of service is based on

the knowledge that every project is unique –

and that custom-tailored solutions serve best.

This is reflected in all our actions. As an

example, for data capture our clients may

choose between paper and different EDC

solutions, including our proprietary EDC sys-

tem, which has been developed for multina-

tional non-interventional studies and gets

enthusiastic feedback from both customers

and end-users. syneed medidata GmbH

combines experience with the quality, dedi-

cation and flexibility of a midsized organiza-

tion. 

So, for almost any trial you can think of, we

provide the expertise you need for turning

data into results.

Address

syneed medidata GmbH

Cicerostraße 21

10709 Berlin · Germany

Phone +49 30 31172751 00

www.medidata.de

info@medidata.de

Contact

Dr. Christian Hucke

Clinical Program Director

christian.hucke@medidata.de

syneed imagingsyneed imaging, the Medical Imaging Core

Lab of syneed medidata GmbH, offers solu-

tions for study planning, protocol develop-

ment, site evaluation, image collection and

processing and conduct of central indepen-

dent reviews with a wide variety of criteria

(e.g. RECIST, 1.0 and 1.1, Choi, Cheson, irRC,

RANO, PERCIST, mRECIST).

Within almost 20 years of operation we have

managed trials in various indications (oncol-

ogy, neurology, radiology, PET diagnostics,

devices) and modalities, and established an

extensive network of medical experts who

support us as consultants and independent

readers. Our experience, flexibility and pric-

ing especially for early phase trials are highly

valued by Biotech clients.

All study data are hosted solely in Germany

on our servers maintained by own IT staff.

Address

syneed imaging & syneed medidata GmbH

Cicerostraße 21

10709 Berlin · Germany

Phone +49 30 31172751 00

Contact

John Uiters

Director Medical Imaging Services

john.uiters@medidata.de

Full clinical and biometric services

for clinical trials and non-interventional

studies

Operational services offered in EU, CEE,

Russia and USA through our established

alliance of partner CROs

Very high staff retention - stable,

experienced teams delivering projects

on time and with highest quality

Pharmacovigilance and Imaging services

for development projects and marketed

products

Best value for money due to

tailor-made services

Contact us: Phone: +49 (0)30 / 2125-4747 E-mail: wachsen@ibb.dewww.ibb.de/wachsen

Our tailored fi nancing are your key to success. Our consultants look forward to meeting you.

Getting your innovation going.

140305_IBBanz_biotop12_210x148.indd 1 05.03.14 12:22

Biotech Networks kBioTOP Berlin-Brandenburg kBioHyTec Network for Biohybrid Technologies kBioResponse kCenter for Molecular Diagnostics and Bioanalytics (ZMDB) kDiagnostikNet-BB kNetwork Glycobiotechology Berlin-Brandenburg kRegenerative Medicines Initiative Berlin-Brandenburg kRiNA Network for RNA Technologies

Scientific Institutions kBerlin-Brandenburg Center for Regenerative Therapies (BCRT) kBrandenburg University of Technology (BTU) kCharité – Universitätsmedizin Berlin kFraunhofer Institute for Applied Polymer Research (IAP) kFraunhofer Institute for Biomedical Engineering (IBMT) kFreie Universität Berlin (FU) kGerman Heart Instiute Berlin (DHZB) kGerman Institute of Human Nutrition (DIfE) kGerman Rheumatism Research Center (DRFZ) kHumboldt-Universität zu Berlin (HU) k Institute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow) kLausitz University of Applied Sciences kLeibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) kLeibniz-Institut für Molekulare Pharmakologie (FMP) kLeibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V. kMax Delbrück Center for Molecular Medicine (MDC) Berlin-Buch kMax-Planck-Institute for Colloids and Interfaces kMax Planck Institute for Infection Biology kMax Planck Institute for Molecular Genetics kMax Planck Institute of Molecular Plant Physiology kRobert Koch Institute kTechnische Universität Berlin (TU) kUniversity of Applied Sciences Berlin (HTW) kUniversity of Applied Sciences Wildau kUniversity of Potsdam

32

BioTOPics 47 | May 2014 BioTOP-Report

P Bioparks

P Networks

P Scientific Institutions

P Companies

33

BioTOPics 47 | May 2014 BioTOP-Report

FHI I

34

BioTOPics 47 | May 2014 BioTOP-Report Biotech Parks

Biotech Parks

The BioCampus Network Berlin-Brandenburg

Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements of every company. This geographic concentration of specific biotech parks is unique in Germany and probably in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers. More than half of the 232 companies are currently utilizing the infrastructure of a publicly or privately managed park. In addition, the young companies benefit from the closeness to science and the permanent contact and exchange.

berlinbiotechparkIn the very heart of Berlin

berlinbiotechpark Management GmbH · Herr Frank Elsner

Max-Dohrn-Straße 8–10 · 10589 Berlin

Phone +49 30 20364205 · Fax +49 30 20364190

info@berlinbiotechpark.de · www.berlinbiotechpark.de

berlinbiotechpark is located on a 86,000 sq.m. site in the

very heart of Berlin, currently offering a total of approx.

63,000 sq.m. of office, laboratory and production space, with

a building potential for another 45,000 sq.m. of rental area.

The site, which is home to Biotech/Pharma/Service Compa-

nies is supplied with a complete range of media for laboratory

and production purposes, with production steam with possi-

bility to upgrade to HP steam, power supply, compressed-air,

nitrogen and other inert gases, cooling water and DI-water , all

being provided at favorables rates.

The infrastructure includes conference facilities as well as

works security and waste disposal services. It is rounded off

by production-related services such as plant engineers and

laboratory technicians, industrial safety engineers, a medical

service as well as best-buy services and communication ser-

vices. Offering flexible growth potential, production-orientat-

ed media equipment and comprehensive industrial-specific

services and infrastructure, berlinbiotechpark is particularly

attractive for growing internationally orientated technology

companies. Furthermore, it offers a permanent base in Berlin

for developing companies that have outgrown the size allowed

by their limited start-up funding. The inner-city location and

the excellent public transport guarantee short ways to all sci-

entific institutions and hospitals of the city.

Biotech Campus PotsdamResearch on the Waterfront

Biotech Campus Potsdam

Steinstraße 104-106 · 14480 Potsdam

Phone +49 331 6601628 · Fax +49 331 6601699

info@biotechcampus.de · www.biotechcampus.de

Contact: Gabriele Ziegler

Just a few minutes away from Potsdam’s central railway sta-

tion in the direction of Caputh, Biotech Campus Potsdam

is located on the Hermannswerder peninsula in the river

Havel. It is owned and operated by Biotech Campus Pots-

dam GmbH, a fully owned subsidiary of the Investment Bank

of the State of Brandenburg.

35

BioTOPics 47 | May 2014 BioTOP-Report Biotech Parks

The biotechnology center is housed in four buildings dating

from around 1,900 and one modern complex and offers a

total of 11,400 sq.m. of laboratory, office, greenhouse and

storage space. With such a large facility at its disposal, it of-

fers biotechnology companies an ideal environment for suc-

cessful operations. All labs are approved as S1 laboratories

and meet the building requirements for approval as S2 labs.

The Hermannswerder site also includes an S3 laboratory as a

special resource. The beautiful, park-like setting of the pen-

insula offers an excellent environment for research activities.

The island hotel and a conference center are located directly

next to the campus.

The site also includes a self-service restaurant and small is-

land shop. The philosophy of Biotech Campus Potsdam was,

and still is, to create the freedom for research and innovation

in the high-tech sector of biotechnology. Reputable firms from

the industry can indeed be found here.

The work carried out by resident companies is multi-faceted,

ranging from green biotechnology, the development of vac-

cines, the development of pharmacologically active substanc-

es based on plant materials, the development and production

of PCR tests for food testing and preclinical contract research

right through to medical technology. A total of 200 employees

work on the site.

Biotechnology Park LuckenwaldeSpace for Expansion

Biotechnologiepark Luckenwalde · c/o SWFG mbH

Im Biotechnologiepark, TGZ I · 14943 Luckenwalde

Phone +49 3371 681100 · Fax +49 3371 681105

bio-luck@swfg.de · www.bio-luck.de

Contact: Dipl.-Ing. Christoph Weber · Director

Located just 25 miles from the new Berlin-Brandenburg In-

ternational Airport (BBI) in the district of Teltow-Flaeming,

the Biotechnology Park Luckenwalde is one of the most

modern facilities of its kind in Germany. It is home to 35

companies from Germany, USA, UK, Korea and Israel with

about 500 employees.

Companies in the park focus on the development and produc-

tion of pharmaceuticals, recombinant proteins and diagnostic

kits, biological/chemical substances for biotech and pharma-

ceutical applications, as well as fine chemicals. There are also

suppliers of medical technology, analytical services, and a

Biotech Education Center. Technical Equipment comprises

completely furnished S2 laboratories (safety workbench, auto-

clave, dishwasher, deionized water, water purification system,

central media supply (compressed air, N2, CO

2, O

2, H

2), stor-

age and cool rooms, pharmaceutical clean rooms category

36

BioTOPics 47 | May 2014 BioTOP-Report Biotech Parks

(B/C), 400 MHz NMR spectrometer, meeting rooms, confer-

ence hall (300 seats), library, restaurant with catering service.

The entire central technique meets GMP/ISO 9001 specifica-

tions. The park management offers comprehensive, individual

services and advice during the settlement and development

of firms, including support for the recruitment of the key staff.

Currently the park offers 9,000 sq.m. labs and office space,

and additional 100,000 sq.m. industrial property ready for

expansion. The park is part of an international and regional

network to assure access regional and to funding sources and

cooperation with universities and hospitals.

Co:bios TechnologiezentrumService for all stages of growth and expansion

co:bios Technologiezentrum GmbH

Neuendorfstraße 20 a · 16761 Hennigsdorf

Phone +49 3302 2021250 · Fax +49 3302 2021257

info@cobios-technologiezentrum.de

www.cobios-technologiezentrum.de

Located in the northwest of Berlin, the co:bios Technology

Center in Hennigsdorf is the congested urban area in Ber-

lin-Brandenburg of biotechnology and life science. In the last

15 years more than 30 companies with approximately 700

international employees have settled on this site.

On more than 10,000 sq.m. we offer service space for

extension to clean rooms (class D/E/F), S1 labs, DI-water sup-

ply, compressed air supply, special gas supply, state of the

art data communication, meeting rooms, conference hall and

more. The building and central technique requirements also

meet the fulfillments for S2 labs for GMP/ISO 9001 based pro-

duction specifications. As a center of excellence for biotech-

nology and life science we have a selected portfolio of service

and advice to young start-ups as well as medium sized com-

panies, in aim to support them across all stages of company

growth. For those companies who have outgrown their limited

start-up funding, we additionally hold 80,000 sq.m. developed

industrial property ready for expansion.

With our holistic approach combining settlement, development,

construction and licensing issues to the point of traditional

management consulting, and on the background of the high

density of innovative, research-intensive and service-oriented

companies on the co:bios biotechnology park Hennigsdorf

we can initiate interesting synergy effects for your business

model. Within this locational advantages the co:bios biotech-

nology park became a magnet for the international healthcare

industry and the percentage of international settlements on

this site is growing, for example from USA, South America,

VAI and Asia.

Campus Berlin-BuchInteraction of Research, Clinics and Companies

Robert-Rössle-Straße 10 · 13125 Berlin

Phone +49 30 94892511 · Fax +49 30 94893812

info@bbb-berlin.de · www.bbb-berlin.de

Contact: Dr. Andreas Mätzold · Executive Manager

Dr. Ulrich Scheller · Executive Manager

37

BioTOPics 47 | May 2014 BioTOP-Report Biotech Parks

Berlin-Buch is the location of one of the largest biotechnolo-

gy parks in Germany, with 31,000 square meters of scalable

lab and office space for start-ups and maturing companies.

Situated to the northeast of the city, the Berlin-Buch Campus

is currently home to 56 companies, 41 of which are biotech

companies; the rest provides support services.

Beside the BiotechPark the Max Delbrück Center for Molecu-

lar Medicine, the Leibniz Institute for Molecular Pharmacology

as well as clinical groups from the Charité University Hospi-

tal within the Experimental and Clinical Research Center are

part of the Campus community. The Campus gives access to

high-end technology platforms, state of the art infrastructure,

interdisciplinary communication, projects and expertise in a

wide range of items, especially in translational research. The

BiotechPark at the Campus Berlin-Buch offers:

k Immediately available lab and office space

k Excellent research and clinical expertise on-site

k Training programs for personnel on spot

k An international community of like-minded people

k Interdisciplinary networks and platforms

The BiotechPark including the Innovation and Incubation Cen-

ter is managed by BBB Management GmbH Campus Ber-

lin-Buch. Acting as a full-service company BBB’s main tasks

are the settlement, accompanying and support of Biotech

businesses.

Berlin AdlershofGermany’s leading Science- and Technology Park

Adlershof Zentren für Biotechnologie und Umwelt

WISTA-MANAGEMENT GMBH

Rudower Chaussee 17 · 12489 Berlin

Phone +49 30 63922221 · Fax +49 30 63922212

terytze@wista.de · www.adlershof.de

Contact: Heidrun Terytze

Head of Center for Biotechnology and Environment

Berlin Adlershof focuses on photonics and optical technol-

ogies, material and microsystems technology, information

and media technology, as well as biological, and environ-

mental technology. There are currently 25 biotech compa-

nies in Adlershof occupying 18,200 sq.m. of lab and office

space. The companies focus on:

k Biotechnology products and procedures development

k Pharmaceutics, medicine, and medicine technology

k Analytics

k Environmental technology

Technical Equipment comprises laboratories with a basic

equipment: security-lockers, laboratory basins, work bench-

es, vacuum supply, preliminary setup for supply of pure gas-

es and compressed air, reconfiguration for further media and

gases, central cooling, preliminary setup for cold water supply

38

BioTOPics 47 | May 2014 BioTOP-Report Biotech Parks

in rental areas, refitting of heat exchanger by the tenant pos-

sible. Adlershof. Science at Work.

Science Park Potsdam-GolmConnecting Excellence

Standortmanagement Golm GmbH

Am Mühlenberg 11 · 14476 Potsdam-Golm

Phone +49 331 237351130

www.wissenschaftspark-potsdam.de · www.goin-potsdam.de

Contact: Friedrich W. Winskowski · Managing Director

Science Park Potsdam-Golm combines cutting-edge

international research and the training of young scientists

in a high-powered location in the immediate vicinity of the

German capital Berlin. Alongside the Faculty of Science and

the Human Sciences Faculty of the University of Potsdam,

three Institutes of the Max Planck and two of the Fraunhofer

Society as well as an innovation center with currently

22 companies operate in Brandenburg’s largest science park.

More than 2,500 people work at Potsdam-Golm and more

than 9,000 students are pursuing their academic qualifica-

tions here. The pleasant and very family-friendly working envi-

ronment on the edge of a nature conservation area, the high

quality of life in and around Potsdam and continuous growth

make Potsdam-Golm a highly attractive location. Profession-

al site management is extending the park infrastructure and

fosters the integration of the capabilities and interests of

all institutions, associations and companies that operate at

Science Park Potsdam-Golm.

The GO:IN Innovation Center offers young technology-based

companies and entrepreneurs a range of office and laborato-

ry spaces along with extensive services and optimal support

for a successful market launch. Close proximity to the other

players at Potsdam-Golm and the intensive networking of the

different institutions and companies here offer perfect condi-

tions for the development and exploitation of synergies.

BioTOPics 47 | May 2014 BioTOP-Report Addresses

AddressesNetworks 40Biotech Parks 40Other Parks 41IP Asset Management 41Universities and Research Centers 41Banks and VCs 41Supporting Organisations 42Pharmaceutical Companies 42Contract Manufacturers 44Contract Research Organisations 44Biotech Companies 46

Addresses

For Companies on the Rise

Equity Financing – building on your strengths!

Are you looking to expand your business and maximize on growth prospects in the technology sector in Germany? Yet, you require some support and equity financing to get your project successfully underway in a new market-place? Then, we are the right partner for you!

We pride ourselves in providing the best in equity financing to our 150 corpo-rate clients totalling over 150 million in strategic financing. We are dedicated to assisting our customers to advance their businesses in new areas and to enable sustainable growth of business and even greater success.

Remember, your success is our success. Let us be part of your success story! Contact us now.

www.ilb.de

Foto

: ILB

40

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Networks

BioHyTec – Verein für Bioanalytik und Biohybrid-Technologien e. V.

BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Bran-denburg. This new field of technology is the interface between biosensor development and microsystems technology. Biohybrid systems open up new applications in pharma-ceutical research, clinical diagnostics, food analysis and genetic engineering.

biohytec.de

BioResponseNetzwerk BioResponse is an interdisciplinary research and development organisation with mem-bers from Brandenburg, Berlin and Saxony. It focuses on the development and market-ing of multiplex assays for diagnostic antibody identification based on the proprietary BioResponse technology, which is comprised of fully automated image analysis of flu-orescence-encoded microparticles and labelled cell structures.

bioresponse.de

DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg

DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro-diagnostics. Members include biotech companies as well research institutes and clinics. Main objectives of the network are: Development of system solutions, optimizing compatibility, close co-operation with leading clinicians and joint marketing.

diagnostiknet-bb.de

Health Capital Berlin-Brandenburg

In order to develop the scientific and economic position of the region, the governments of the states of Berlin and Brandenburg have put the master plan “Healthregion Berlin Brandenburg” into effect. Its key to a continued success is a continued close interplay between research, development and education7vocational training with production, application and supply. All of these activities are integrated and coordinated through the Network “Gesundheitswirtschaft Berlin Brandenburg” under the brand of “Health-Capital”.

healthcapital.de

Regenerative Medicine Initiative Berlin-Brandenburg

The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of excellence for Regenerative Medicine particularly for cell-based medical biotechnolo-gy. The RMIB promotes networking in the field and supports the further development of clinical studies and education programs. The initiative fosters the collaboration between universities, research institutes, companies (including SMEs) and organizations in the field of science and technology.

rmib.de

RiNA -Netzwerk RNA-Technologien

The RNA-Network provides ongoing support and funding for the development of RNA technologies with the goal to commercialize the results. One main focus is the improve-ment and application of the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosynthesis systems and analyse the structure and function of RNA molecules. The RiNA RNA-Network encourages co-operation and information exchange between academy and industry.

rna-network.com

Zentrum für Molekulare Diagnostik und Bioanalytik

The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre op-erated under the auspices of the Fraunhofer Institute for Biomedical Technology and the Charité – Universitätsmedizin Berlin in close cooperation with the region’s company networks. The aim is to bring together regional expertise in basic research, technology development, clinical research and industrial cooperation initiatives to set up joint proj-ects that will speed up the development of in vitro-diagnostics “Made in Berlin-Bran-denburg”.

zmdb.de

Biotech Parks

berlinbiotechpark berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently offering a total of approx. 57,000 m² of office, laboratory and production space, with a building potential for another 45,000 m² of rental area. Offering flexible growth po-tential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing inter-nationally orientated technology companies.

berlinbiotechpark.de

Biotech Campus Potsdam Just a few minutes away from Potsdam’s central railway station in the direction of Ca-puth, BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg.

biotechcampus.de

Biotechnologiepark Luckenwalde Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg Internation-al Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 35 companies with about 500 employees from Germany, USA, UK, Korea, and Israel.

bio-luck.de

Co:bios Technologiezentrum GmbH

The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities and a selected portfolio of services and advice to young start-ups as well as medi-um-sized companies. Therefore Hennigsdorf is a center of excellence for life sciences, especially in the field of red biotechnology and medical technology.

cobios- technologiezentrum.de

Campus Berlin-Buch bbb Management GmbH

Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the campus is currently home to 56 companies, 41 of which are biotech companies; the rest provide support services.

bbb-berlin.de

Adlershof Zentren für Biotechnologie und Umwelt

Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on Photonics and Optics, materials and microsystems and media, biotechnology, and environment. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space.

adlershof.de

41

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Other Parks

GO:IN Golm Innovationszentrum GmbH

Science Park Potsdam-Golm is one of the most innovative and promising locations in Brandenburg. In the GO:IN facility, innovative companies will find an excellent working environment where they will benefit from the synergy effects of the location and the specific equipment offered by its laboratories. The location provides a wide range of services and consulting, as well as integration into the existing regional networks.

wissenschaftspark-potsdam.degoin-potsdam.de

Innovationspark Wuhlheide So far 140 companies have decided to locate at the Wuhlheide Innovation Park, where the creative environment and service-oriented management provide important stimuli with respect to product development and innovation. Our companies have attractive office accommodation, workshops, laboratories and service areas at their disposal. Furthermore, they also have the opportunity to acquire fully developed investment sites for the evolution of their company! The location stands for successful new businesses, growth and long-term perspectives.

ipw-berlin.de

IP Asset Management

Ascenion Ascenion advises public life science research institutions, universities, hospitals, free-lance inventors and companies in all aspects of intellectual property asset manage-ment.

ascenion.de

ZukunftsAgentur Brandenburg GmbH Brainshell

Brainshell is an independent consulting agency specializing in intellectual property services for businesses.Brainshell manages and markets the patent portfolios of all colleges, universities, and research institutes in the State of Brandenburg.

brainshell.de

Universities and Research Centers

BAM Federal Institute for Materials Research and Testing bam.de

Berlin-Brandenburg Center for Regenerative Therapies (BCRT) b-crt.de

BfR Federale Institute for Risk Assessment bfr.bund.de

Brandenburg University of Technology tu-cottbus.de

Charité - Universitätsmedizin Berlin charite.de

Deutsches Rheuma-Forschungszentrum Berlin drfz.de

Fraunhofer Institute for Applied Polymer Research (IAP) iap.fraunhofer.de

Fraunhofer Institute for Biomedical Engineering (IBMT) ibmt.fraunhofer.de

Freie Universität Berlin fu-berlin.de

German Heart Instiute Berlin dhzb.de

German Institute of Human Nutrition (DIfE) dife.de

Humboldt-Universität zu Berlin hu-berlin.de

htw Berlin – University of Applied Sciences htw-berlin.de

Institute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow) hzg.de

Institute for the Reproduction of Farm Animals Schönow Inc. ifn-schoenow.de

Lausitz University of Applied Sciences fh-lausitz.de

Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) atb-potsdam.de

Leibniz-Institut für innovative Mikroelektronik ihp-microelectronics.com

Leibniz-Institut für Molekulare Pharmakologie (FMP) fmp-berlin.de

Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch mdc-berlin.de

Max Planck Institute for Infection Biology mpiib-berlin.mpg.de

Max Planck Institute for Colloids and Interfaces mpikg.mpg.de

Max Planck Institute for Molecular Genetics molgen.mpg.de

Max Planck Institute of Molecular Plant Physiology mpimp-golm.mpg.de

Robert Koch Institute (RKI) rki.de

Technische Universität Berlin (TU) tu-berlin.de

University of Applied Sciences Berlin beuth-hochschule.de

University of Applied Sciences Wildau tfh-wildau.de

University of Potsdam uni-potsdam.de

Banks and VCs

BC Brandenburg Capital GmbH bc-capital.de

Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge lbb.de

Berliner Volksbank eG berliner-volksbank.de

42

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Banks and VCs

bmp Life Science AG bmp.com

Business Angels Club Berlin bacb.de

Commerzbank AG commerzbank.com

Creathor Venture creathor.de

Demeter Partners demeter-partners.com

Deutsche Bank AG db.com

High-Tech Gründerfonds Management GmbH high-tech-gruenderfonds.de

IBB Beteiligungsgesellschaft mbH ibb-bet.de

Investitionsbank Berlin ibb.de

Investitionsbank des Landes Brandenburg ilb.de

KfW-Mittelstandsbank kfw-mittelstandsbank.de

Peppermint Venture Partners GmbH peppermint-vp.de

Ventegis Capital AG ventegis-capital.de

XLHealth xlhealth.de

Supporting Organisations

Berlin Partner für Wirtschaft und Technologie GmbH

Support of international and domestic companies in all issues regarding locating to Berlin.

berlin-partner.de

Coaching Bonus Specific Coaching offers for innovative high tech companies. coachingbonus.de

Investitionsbank Berlin (IBB) Company financing and consultation on subsidies and processing grant applications in Berlin.

ibb.de

Investitionsbank des Landes Brandenburg

Company financing and consultation on subsidies and processing grant applications in Brandenburg.

ilb.de

Landesamt für Gesundheit und Soziales Berlin (LAGeSo)

One Stop Agency for all licensing and approvals, for questions concerning biomed-icine, biotechnology and pharmaceuticals and for more general issues connected with health, disease control and public health in Berlin.

berlin.lageso.de

Technologie Stiftung Brandenburg

The technology Foundation Brandenburg is dedicated to the advancement of sci-ence and research, especially in the field of innovative technologies.

ts-bb.de

Technologiestiftung Berlin The Technology Foundation Berlin is a public private partnership in the German capital region to develop science and industry networks for technology transfer, joint projects, and regional innovation strategies.

tsb-berlin.de

ZAB Zukunftsagentur Brandenburg

The Brandenburg Economic Development Board functions as a one-stop agency for all kinds of business support services.

zab-brandenburg.de

ZAK Zentrale Anlauf- und Koordinie rungsstelle Senatsverwaltung für Wirtschaft, Technologie und Forschung

Helps you find your way through the Berlin administration. Supports complex urban development policy and investment projects.

berlin.de/sen/wirtschaft/zak

Pharmaceutical Companies

Advance Pharma GmbH Contract manufacturer of solid drugs.Galenic development and admissions, analyt-ics and microbiology, coating and granulation (organic and aqueous), compacting, packaging.

advance-pharma.eu

ALPHAMADE GmbH Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding, omega-3 fatty acids, cytostatics.

alphamade.de

AstraZeneca We are a global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. We operate in over 100 countries and our medicines are used by millions of patients worldwide. AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK – two companies with similar science-based cultures and a shared vision of the pharmaceutical industry.

astrazeneca.com

Bausch & Lomb Dr. Mann Pharma

Bausch & Lomb is the eye health company dedicated to perfecting vision and en-hancing life for consumers around the world. Core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products.

bausch-lomb.de

Bayer Pharma Aktiengesellschaft Bayer Pharma is one of the ten largest specialty pharmaceutical companies in the world and the company's goal is a leading market position in each of its specialist fields. With its distinctive expertise in research, the company develops new medi-cines and therapies which make an essential contribution toward improving patient's quality of life.

bayerhealthcare.com

43

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Pharmaceutical Companies

BERLIN-CHEMIE Aktiengesellschaft

BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was formed in 1886 and is headquartered in Florence, was developed over the generations to become a global, owner-managed pharmaceutical company. Re-search is centred on the development of innovative drugs for the following areas: inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease.

berlin-chemie.de

Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH

CPL S: Custom synthesis development of active pharmaceutical ingredients (API’s), Contract manufacture of active pharmaceutical ingredients from laboratory to kilo-scale, Pharmaceutical analysis.

cpl-sachse.de

Daiichi Sankyo Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

daiichisankyo.com

Dr. Kade Pharmazeutische Fabrik GmbH

The company’s activities concentrate on the production and marketing of drugs in the fields of gynecology, proctology, pain relief/ rheumatism and urology. The poten-tial of proven drugs is expanded systematically by galenic developments to produce innovative products.

kade.de

Haupt Pharma AG With&nbsp,nine production sites Haupt Pharma is one of the leading contract man-ufacturers for pharmaceutical products in&nbsp,the world&nbsp,today.&nbsp,About 2.000&nbsp,employees produce for an established clientele of more than 200 im-portant international pharmaceutical companies, amongst which 15 of the interna-tional TOP 25.

haupt-pharma.de

Heyl chemisch pharmazeutische Fabrik GmbH & Co. KG

HEYL is an independent, entrepreneurial family business that has its headquarters in probably the liveliest German metropolis, Berlin, since its establishment in 1926. In cooperation with our international subsidiaries, the main focuses of our work are the Regulatory Affairs and marketing of medicines as well as the sale of active pharma-ceutical ingredients (API's) and special chemicals.

heyl-berlin.com

Klosterfrau Berlin GmbH For more than 175 years Klosterfrau has been developing, manufacturing and mar-keting pharmaceutical products. The profile of traditional yet modern natural med-icines has grown significantly in recent times. Based on the latest scientific discov-eries combined with the development of new markets, the range is constantly being expanded with innovative products.

klosterfrau.de

medphano Arzneimittel GmbH medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective phar-maceutical preparations. Main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gas-tro-intestinal disorders, vitamins, expectorants, lipid-lowering agents, ophthalmics, cosmetics, food supplements, diet foods and foods.

medphano.de

MUCOS Pharma GmbH & Co.KG As a specialist in enzyme preparations Mucos supplies a steadily growing market with specific and variably dosed enzyme combinations. The company leads the world market in oral enzymes for therapeutic purposes.

mucos.de

Pfizer Pharma GmbH Pfizer is the world's largest research-based biomedical and pharmaceutical com-pany.

pfizer.de

Pharma Action GmbH Pharma Action has extensive expertise in global pharmaceutical marketing and man-ufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad.

pharma-action.com

PharmaMar GmbH PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondel-is® is the first marine-based antitumour drug. PharmaMar has four other compounds in clinical development: Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme. PharmaMar GmbH, the German subsidiary, was officially established in November 2013 in Berlin.

pharmamar.com

Piramal Imaging GmbH Piramal Imaging is a start-up business within the Life-Science division of the Mum-bai-based Piramal Enterprises Group. The company is dedicated to the clinical re-search & development and the global commercialization of Nuclear Medicine / Mo-lecular Imaging products for detection, characterization and monitoring of disabling and life-threatening diseases in neurology, oncology and the cardio-vascular space.

imaging.piramalenterprises.com

Sanofi-Aventis Deutschland GmbH

Sanofi-aventis is a leading global pharmaceutical company based in Paris and oper-ating in over 100 countries. R&amp,D teams work on a global approach to patients, offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, the central nervous system disorders and internal medicine.

sanofi-aventis.de

Shire Deutschland GmbH Shire’s strategic goal is to become the leading specialty biopharmaceutical compa-ny that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases.

shire.de

44

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Pharmaceutical Companies

Spreewälder Arzneimittel GmbH Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.

spreewaelder-arzneimittel.de

Steiner & Co. Deutsche Arzneimittelgesellschaft mbH & Co. KG

Production and marketing of pharmacy and prescription drugs, particularly plant-based drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and urological drugs), analgesics and mineral preparations.

steinerarznei-berlin.de

Steripharm Pharmazeutische Produkte GmbH & Co. KG

Production and marketing of folic acid products. steripharm.de

Takeda GmbH Takeda is Japan´s and Asia´s largest pharmaceutical company and among the lead-ing global companies of its branch, represented in more than 70 countries. Takeda committed itself for a better health care of patients all over the world by innovations in medicine. Its therapeutical core areas are metabolic, cardiovascular, inflammatory, immune and respiratory diseases, diseases of the central nervous system, oncology, gastroenterology and pain.

takeda.de

Teva GmbH Teva in Germany is the leader in generics and an expert in innovative brand busi-ness. The German headquarter is located in Ulm. Patent-protected medicines from the fields of neurology, oncology, pain management and respiratory diseases are marketed by Teva Specialty Medicines in Berlin. Teva Specialty Medicines’ primary area of success is neurology. The first product to be come from the company's own development facility contains the active ingredient glatirameracetate and is the mar-ket leader among drugs used to treat multiple sclerosis. Another product from Teva’s own research laboratories, is a standard in the treatment of Parkinson’s disease.

teva.de

Contract Manufacturers

Advance Pharma GmbH Contract manufacturer of solid drugs.Galenic development and admissions, analytics and microbiology, coating and granulation (organic and aqueous), compacting, pack-aging.

advance-pharma-berlin.de

ALPHAMADE GmbH Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding, omega-3 fatty acids, cytostatics.

alphamade.de

Ayanda GmbH & Co. KG Ayanda is an innovative business partner and manufacturer of consumer ready phar-maceuticals and food supplements. In Pritzwalk, Brandenburg, the company has a pharmaceutical soft gel encapsulation plant.

ayanda.com

Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH

CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredi-ents (API’s); Contract manufacture of active pharmaceutical ingredients from laborato-ry to kiloscale; Pharmaceutical analysis.

cpl-sachse.de

Haupt Pharma AG With nine production sites Haupt Pharma is one of the leading contract manufacturers for pharmaceutical products in the world today. About 2.000 employees produce for an established clientele of more than 200 important international pharmaceutical compa-nies, amongst which 15 of the international TOP 25.

haupt-pharma.de

Pharma Action GmbH Pharma Action has extensive expertise in global pharmaceutical marketing and man-ufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical in-dustry in Europe and abroad.

Pharma-action.com

Spreewälder Arzneimittel GmbH Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.

spreewaelder-arzneimittel.de

Contract Research Organisations

analyze & realize ag analyze & realize ag is a leading CRO and consulting firm, which primarily give com-plete advice and guidance to companies in the natural products sector.

analyze-realize.com

Allied Clinical Management GmbH

The CRO has broad experience in monitoring and managing phase I to phase IV clin-ical trials including advanced therapy medicinal product (ATMP) trials as well as in accompanying and conducting medical device trials and post-marketing surveillance.

allied-clinical.com

Assign International GmbH Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with six offices in five countries.Our expertise meets development requirements of pharmaceutical and biotechnological industries. We manage clinical trials from study set-up to final clinical report.Our services, among others, comprise Data Management and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Labo-ratory Services and Quality Management.

assigngroup.com

BLS Preclinical Services BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS provides a range of highquality and integrated preclinical services in animal mod-els. Through our highly skilled scientific partners we provide a “one-stop” service and tailored solution. We take the time to understand your business needs and provide com-prehensive tailored solutions either in-house or in co-operation of our network. We are backed by a highly skilled scientific team with a wealth of experience in all disciplines of preclinical development.

bls-germany.com

45

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Contract Research Organisations

CBR Biotech Strategies GmbH CBR International Corporation is a global, full-service product, clinical, and regulatory compliance development group dedicated to providing comprehensive consulting ser-vices. We understand commercial pressures and regulatory constraints of biopharma-ceutical product development and offer full support and guidance to all of our clients. Our experienced staff and consulting affiliates offer detailed and strategic services to members of the biotechnology, pharmaceutical, and device industries worldwide.

cbrintl.com

Charité Research Organisation GmbH

Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration with Berlin‘s famous Charité University Hospital. This relationship fosters a level of co-operation with centers of clinical excellence that we think is unique in the industry. The CRO offers a whole new approach to the concept of partnering with centers of clinical excellence to facilitate access to patients, clinical expertise and specialist methodolo-gies in support of early clinical development programs.

charite-research.org

Cooperative Clinical Drug Research and Development (CCDRD) AG

CCDRD is an independent contract research organization (CRO). CCRDR is dedicated to offer creative and innoative full service from planning to market authorization to its customers in the pharmaceutical, biotechnological and medical device industry.

ccdrdag.com

CSG Clinische Studien Gesellschaft mbH

Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed on aligning clinical research with public health demands, with special attention to fa-cilitating access by physicians and patients to clinical studies.CSG cooperates closely with the largest research institute for public health in Germany, the IGES Institut.

csg-germany.com

Dr. Notghi Contract Research Dr. Notghi Contract Research GmbH is a service provider for large, medium and small-sized companies in the pharmaceutical, generics and biotechnology industries. We support and advise you in the conduct and management of national and international projects.

notghi.com

Klinische Forschung Berlin GbR Klinische Forschung Berlin is a study centre that implements clinical studies from phases IIA to IV for the pharmaceuticals industry.

klinische-forschung-berlin.de

Klinische Forschung Gruppe Nord GmbH

The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of independent investigator institutes with five centres in Northern Germany, two of them in Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to 250 patients. Phase II and III studies are the core competence. The test centres have altogether 30 overnight accommodation places for phase I and IIa studies.

kfgn.de

Lampe & Company GmbH & Co. KG

Lampe & Company is a consulting firm specialized in multidimensional analysis of biomedical literature for evidence-based decision making. Our team of experts com-bines industry expertise with our unique L-Matrix Method and exclusive L&C relational database to deliver critical information to leading decision makers of pharmaceutical, life sciences, and medtech companies.

lampeandcompany.com

MEDIS RESEARCH GROUP MEDIS RESEARCH GROUP is a partnership of clinical research services providers with a joint mission to combine clinical research expertise and provide complete service solutions across all stages of the clinical development process.

medis-research.com

OSMUNDA Medical Device Service Group

OSMUNDA is the largest Chinese clinical trial CRO and service provider for the medical device and in-vitro diagnostic industry. Over 2000 international clients have entrusted our expertise in regulatory affairs, clinical trials and industrial distributor/supplier re-sources to achieve their business goals.

osmundagroup.com

PAREXEL International GmbH The German subsidiary of the US clinical research organization PAREXEL employs more than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are performed each year.

parexel.com

PharmaLex GmbH PharmaLex is one of the leading service providers in the International pharmaceutical business. The company is dedicated to the development, registration and marketing authorization, market access and product maintenance of medicinal / biotechnological products and medical devices, worldwide. The corner stones of PharmaLex’ successful co-operation with companies of all sizes and specializations are very high quality of work, reliability, efficacy, flexibility and anticipatory strategic planning.

pharmalex.com

Sacura GmbH Sacura is a full-service contract research organization granting a high level of quality (FDA approved), flexible structures and qualified staff.

sacura-cro.com

WITEGA Laboratorien Berlin-Adlershof GmbH

WITEGA Laboratorien Berlin-Adlershof GmbH is a medium-sized company specializing in the realization of organic customer syntheses. Our customers are companies from the chemical and pharmaceutical industries as well as from other technology fields. The main focus of our activities is the lab-scale custom synthesis of organic building blocks, intermediates and target structures and of isotope-labeled compounds (D, 13C, 15N) for chemical and pharmaceutical research and development. The company is also a supplier of analytical standards for residue analysis (especially in veterinary medicine).

auftragssynthese.com

46

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

3B Pharmaceuticals GmbH 3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin, Germany. The company is dedicated to the development of pep-tide-based pharmaceutical and diagnostic products. 3BP is pursuing projects in he-mophilia and nuclear medicine.

3b-pharma.com

8sens.biognostic GmbH 8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for different markets (human and veterinary diagnostics, food control). Our products are the QuickSens®-tests for h-FABP, TropI, CRP and hs-CRP and the Reader for quantifi-cation QuickSens®OMEGA. Development-on-demand, feasibility studies and produc-tion-on-demand are also offered.

biognostic.de

ABiTEP GmbH The ABiTEP GmbH is working in development and production of biotechnological prod-ucts for sustainable agriculture. The team of ABiTEP works for development of non GMO customer specific technologies in laboratory scale and scale up with modern equipment and Know how. Capacities for fermentation up to 5.000 L, down stream equipment as well as freeze drier with capacity of 90 L are available for services. A molecular biology lab is available for basic science.

abitep.de

Accelero Bioanalytics GmbH Accelero® Bioanalytics GmbH is a biotech CRO focussing on GxP compliant bioanalyt-ical ligand binding assays. The company supports PK and PD preclinical/ clinical drug development on microRNA, miRNA, siRNA, aptamers, plasmid APIs, antisense drugs, as well as peptide hormones, biosimilars, antibody therapeutics, or cell-based thera-peutics (ATMP). The Applied Biosystems Viia7 real-time qPCR system with IVD label for human Dx operates in full compliance to Good Laboratory Practice (GLP).

accelero-bioanalytics.com

Acuros GMBH Development of osmotic micropumps for medical or microfluidic applications.The in-novative technology enables new options in liquid handling – from disposable micro-pumps for drug delivery to precision micropumps for lab-on-a-chip development.

acuros.de

Adrenomed AG Development of biologics against severe sepsis. adrenomed.com

Aevotis GmbH The core competencies of aevotis lie in the targeted conversion of simple carbohy-drate containing substrates (e.g. agricultural by-products, waste streams, inexpensive sugars) to high-value carbohydrate based products, their characterization, processing and testing. Marketable products include novel /optimized enzymes, expression sys-tems,&nbsp, specialized biotransformation and down-stream processes, customized oligomers and polymers for food and non-food uses.

aevotis.com

AFOSA GmbH Development, production and marketing of diagnostics (ELISA kits), primarily for use in veterinary medicine.

afosa.com

Aglycon Mycoton GmbH Aglycon Mycoton GmbH is active in the research, development and application of bio-polymers as well and their manufacture and the sales and marketing of products based on these.

aglycon-mycoton.net

AJ Innuscreen GmbH The AJ Innuscreen GmbH is a young life science company working in the field of bio-technology and boosts the life science unit of Analytik Jena AG. Innovative technologies and products are developed and produced for the isolation and purification of nucleic acids. Reagent systems for molecular biology, as well as technologies and products for molecular diagnostics, are also included in the product portfolio. The company is EN ISO 9001:2008 and EN ISO 13485:2003 + AC:2009 certified.

aj-innuscreen.de

Alacris Theranostics GmbH Alacris Theranostics GmbH is a company based in Berlin specialised in developing new approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. Alacris is applying a systems biology approach that has been de-veloped in the Department of Prof. Lehrach at the Max Planck Institute for molecular Genetics and is exclusively licensed as ModCellTM to Alacris.

alacris.de

Alcat Europe GmbH Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the orig-inal developer of the Alcat test technology. The company is specialized to identify intol-erant reactions of the leucocytes to foreign substances like foods, drugs or chemicals.

alcat-europe.com

Algenol Biofuels Germany GmbH The company focuses on the biotechnological use of cyanobacteria, especially the development and optimization of cyanobacteria for the production of environmentally friendly biofuels and chemical feedstocks.

algenol.com

ALRISE Biosystems GmbH ALRISE is a drug delivery company that specializes in the nano- and micro-encapsu-lation of active ingredients. Using its globally patented ImSus® technology, ALRISE are developing parenteral deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly large pharmaceutical companies who are developing improved administration forms for active ingredients whose patents are expiring togeth-er with ALRISE as part of their “Product Lifecycle Management”.

alrise.de

Amal Therapeutics S.A. Amal Therapeutics SA is a Swiss biotech start-up company and spin-off from the Uni-versity of Geneva with a subsidy in Berlin. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.

amaltherapeutics.com

Amocol Bioprocedures Ltd. Amocol Bioprocedures Ltd is a life science research & development and manufacturing company headquartered in Germany. Our mission is to supply innovative affinity chro-matography media products and protein purification tools for research scientists and clinical customers in public sector institutes and industry.

amocol.com

AnaKat Institut für Biotechnologie GmbH

AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of pharmaceutical ingredients.

anakat.de

47

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

Analyticon Discovery GmbH AnalytiCon is a biotechnology company focusing on the development of compound libraries consisting of natural product (NP) and synthetic small molecules. As the glob-al market leader in NP small molecule screening compounds, AnalytiCon is the only company which is able to provide vast collections with completely disclosed structural information. As a pure compound provider the company is offering its products and services to the pharmac., chemical, biotech, cosmetical and nutraceutical industry.

ac-discovery.com

Analytisches Zentrum Biopharm Berlin GmbH

Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization pro-viding services on pharmaceutical analysis and bioanalysis for active compounds in the dosage form, for the quantitative determination of analytes in a biological matrix and also the determination of physicochemical parameters of chemicals according to OECD guidelines. AZB carries out these services in compliance with GLP and GMP and has the GLP certificate.

analytisches-zentrum-biopharm.de

AnaTox GmbH & Co. KG The AnaTox GmbH & Co. KG deals with the development and optimization of analytical methods and devices for HPLC and dissolution.

anatox.de

Anau Berlin-lab GmbH Development and distribution of lab devices.

ANiMOX GmbH Development of applications for the use of natural peptide / amino acid mixtures in chemistry and biotechnology, f.i. as a scavenger material in formaldehyde bounded formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotech-nological fermentation processes, distribution of a technology for the production of such basic materials from raw and residual materials.

animox.de

Aokin AG Aokin AG is a Berlin biotechnology company that is specialized in the development and commercialization of innovative analytical systems on the base of the rapid kinetic assay technology. The aokin systems are unique in their precision and operating speed. Areas of application are food and antibody analytics as well as clinical diagnostics. We also offer laboratory services in the area of food analytics, Pharmacoanalytics and chemical synthesis.

aokin.com

ARGUS Umweltbiotechnologie GmbH

ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remedi-ation of contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate a specific remediation program in each different pollution case considering economic aspects beside ecological aspects. All necessary treatment steps can be planned and carried out. The combination of microbiological steps with classic pro-cesses leads to a successful remediation of complex contamination.

argus-umwelt.de

Artemiflow GmbH Artemiflow is a spin-off from the Max Planck Institute of Colloids and Interfaces (MPIKG). By the industrial use of an international patent held by MPIKG, Artemiflow uses a new process to produce Artemisinin from dihydroartemisinic acid (DHAA). DHAA is avail-able in abundance in the waste of the current production process for Artemisinin.

artemiflow.com

ASCA GmbH Angewandte Synthesechemie Adlershof

ASCA is a partner for contract research in the field of medicinal chemistry. The syn-thesis and optimization of lead structures, the development of new active structures and their check on a laboratory scale are offered. We take a lot of care on working out the synthetic schemes, rapid preparations and exact analysis of the samples. All our results are carefully documented for our customers. Access to literature databases and in-house analytical facilities are available.

asca-berlin.de

Astra Biotech GmbH Astra Biotech GmbH offers high quality reagents, allergens, antibodies, recombinant proteins, and assays for the determination of hormones, allergies, tumour markers and infectious diseases. Quality is one of the key cornerstones on which Astra Biotech main-tains its reputation and with which we strive to increase customer satisfaction and gain growing customer loyalty. We take great pride in our highest quality assays, which are all IVD compliant and therefore suitable for direct, accurate and reproducible diagnostic purposes, as well as for research.

astrabiotech.de

ATLAS Biolabs GmbH ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as genome wide gene expression and SNP analysis, CGH analysis and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechno-logical and diagnostic enterprises.

atlas-biolabs.com

Attomol GmbH Molekulare Diagnostika

The company’s aim is to develop, produce and distribute medical diagnostics for hu-man medicine in the field of molecular genetics, infectious and autoimmune diseases.

attomol.de

AudioCure Pharma GmbH AudioCure is focus on the clinical development of drug candidates for neurodegener-ative diseases with high unmet medical need.

audiocure.de

AutoTissue GmbH The company is engaged in the development, production and marketing of medical de-vices for cardiovascular surgeons. The products are specially made for the patients and have less side effects. The first certified product was a pulmonary heart valve (Matrix P) for the right ventricular outflow tract reconstruction (RVOT). The second product is also a heart valve which considerably shortens the operation time (Matrix P plus). Meanwhile a complete glutaraldehyde free valve is available called Matrix P plus N.

autotissue.de

Avitop GmbH Avitop is focusing on probiotics and food concepts with specific health indications. Based on the highest scientific standards, we develop a new generation of probiotics and food with unmet specific functions.We deliver the food industry with new and spe-cific solutions for actual and future health challenges facing modern society.

avitop.de

48

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

Bbi-biotech GmbH In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In addition, bbi-biotech develops components - in especially disposable ones - for the preparation of a new generation of fermentors and bioreac-tors and offers consulting and planning services for biotech projects, its implementation and services.

bbi-biotech.com

BEB BioEnergy Berlin GmbH Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropow-er plants, Preplanning, Feasibility Studies and Research activities in the field of renew-able energies, Optimization of the process in existing biogas plants.

bebgmbh.de

BG Berlin-Genetics GmbH BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in genetic diagnostics. We are a team of experienced human geneticists and have worked for many years in the field of human genetic science and human genetic diagnostics. Our aim is the development of innovative cooperation concepts, to connect classical patient-based medical care centers with modern technology-based service centers. In future, these cooperation forms will enable efficient, high quality, and patient-based genetic diagnostics.

bg-berlin-genetics.de

Bioanalyt GmbH Bioanalyt develops and distributes the worldwide first easy-to-use and portable test kits for the analysis of vitamins and micro nutrients. The iCheck-iEx test kits enable food pro-ducers, food authorities and NGOs to monitor their ongling food programms more effi-ciently and at low-cost. The company was founded in 2006 by Prof. Dr. F. J. Schweigert as a spin-off of the University of Potsdam. Read more on our website bioanalyt.com.

bioanalyt.com

Bioassays GmbH Service related to the development of medical in vitro-diagnostic products. Basic sci-ence to clinical development. Profiling of biomarkers in clinical trials.

bioassay-online.de

Biochrom AG Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and others) and sterile liquids. They are distributed to universities, industrial cell culture laboratories and industrial manufacturers. Service is of special significance for users of cell cultures. Special media developments and production optimizations are offered.

biochrom.de

BIOCYC Gesellschaft für Biotechnologie und Recycling mbH & Co.KG

Production of bio-chemicals, peptides, in vitro-diagnostics, test-kits. Development of consumer service for peptides and biochemicals.

quartett.com

BioGenes GmbH BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) development company with outstanding problem solving capabilities specializing in challenging projects that are carried out by an exceptionally experienced and inter-disciplinary team.

biogenes.de

Bioline GmbH Our mission is to provide customers with a range of products which are fast and easy to use, guaranteed to work and developed by scientists who understand what our cus-tomers are trying to achieve so they can focus on their scientific goals. Bioline reagents are used by molecular biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology.

bioline.com

BioMedion GmbH IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term-Archiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of Computerized Systems according to GAMP4/5.

biomedion.com

Biopract GmbH Service and Additives (enzymes, trace elements, microbes) for biogas and waste wa-ter sludge treatmentEnzyme analysis in agriculture industry Contract reserach feed additives.

dsmbiogas.com

Biorefinery.de GmbH Based on main precursors of plants, carbohydrates in kind of sugar, starch and cel-lulose, and proteins, the biorefinery.de company has developed four complex product lines (Biorefinery systems) which leads to a great number of valuable products with the help of chemistry and biotechnology.

biorefinery.de

BioRepro GmbH BioRepro is the first pharmac. company, whose core competency is the breeding of leeches under controlled laboratory conditions for medical therapies. We concentrate on the establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allowing scalability to supply medical demand. Additionally, through the re-initiation of fundamental research, we will gain deeper un-derstanding of further potential in medical and cosmetic treatment areas.

biorepro.de

BioS Biotechnologie Schönow GmbH

Embryo transfer and associated biotechnologies in animals. Service, training and re-search in this field.

bios-schoenow.de

BioSilta Europe GmbH BioSilta is an international company that specializes in advanced tools for microbial cell cultivation, protein production, enzyme screening and food spoilage testing. The patented EnBase® technology resembles fed-batch mode and provides a cultivation environment with glucose-control, pH maintenance and inhibition of growth-limiting metabolites without the need for traditional mechanical pumps. EnBase® is provided in ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and it?s products offer customer solutions from multi-well plates to small-scale bioreactors. Learn more about our products and applications at biosilta.com.

biosilta.com

BIOSYNTAN Gesellschaft für bioorganische Synthese mbH

BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of mod-ified peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer poly- and monoclonal antibodies.

biosyntan.de

49

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

Biotech-Laboratorium für Environment BLE GmbH

Development of detection systems which are able, economically and rapidaly, to detect oil contaminations and industrial oil waste, in soil and in water and their biological de-pletion. The BLE GmbH is concerned with the biological degradation of oil contamina-tions and the development of a set of bio-preparations consisting of different bacterial strains which break down oil.

mobiclup.de

biotechrabbit GmbH biotechrabbit GmbH is determined to offer the newest and best life science products and innovative solutions to scientists leading the fight againstdisease and fueling our lives with innovations. We supply ultra pure enzymes and high-quality antibody ser-vices for diagnostics and a life science product portfolio(including reagents for PCR and nucleic acid purification)for molecular biology and proteomics. The biotechrabbit advantage is our combination ofpassion for excellent research with the agility of true entrepreneurship.

biotechrabbit.com

BIOTECON Diagnostics GmbH BIOTECON Diagnostics has been well known as a qualified partner in the field of mo-lecular and microbiology for the last 13 years. We focus on development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverage industry as well as for producers of pharmaceuti-cals and cosmetics.

bc-diagnostics.com

BioTeZ Berlin-Buch GmbH Services (Custom DNA and RNA Oligonucleotide synthesis, Immuno affinity columns) - Development of Enzyme Immunoassays, e.g. for Therapeutic Antibodies- Bio Conju-gates - Immobilization of Bio Molekules for better Signalling-R&D (Aptamer).

biotez.de

BIOWORX -Biotechnologielabor- Thomas Grimm

BIOWORX offers services in the fields of contract research for customer-specific Bio-transformations, the screening, isolation and production of Biocatalysts from microor-ganisms and plants and the bioanalytic syntheses. Further organic compounds and metabolites will be synthesized with enzymes for customer in kg scale.

bioworx.de

BiRDS Pharma GmbH BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field of drug development to pharmaceutical and biotech companies, including man-agement of drug development projects as well as consulting services. The company also pursues own drug development projects based on intellectual property generated within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Sub-stitution Technology (AST).

birdspharma.com

Blue Biolabs GmbH Blue Biolabs is a spin-off company from the TU-Berlin, which specialises in the devel-opment of products and services in the field of environmental analysis using methods of microbiology and molecular biology.

bluebiolabs.de

Botiss medical AG Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss is the leading German specialist for dental bone and tissue regeneration (BTR). We focus on the development of innovative regenerative materials and clinical market-ing / distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue Bank Austria is a leading European manufacturer of allogenic materials for hard tissue regeneration.

botiss.com

BST Bio Sensor Technology GmbH

BST develops and produces biosensors to provide high quality analysis at moderate prices. In 1982 BST brought on the market the first multi-way biosensor based blood glucose analyzer in Europe and is since then market leader in Europe. Today BST sells more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufac-turer of POCT and laboratory instruments.

bst-biosensor.de

Caprotec bioanalytics GmbH Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows sepa-ration and isolation of proteins based on functionality. For many applications, CCMS is clearly superior to conventional methods - thus addressing an unmet need in the pro-teomics research community. The company is commercializing the CCMS technology through ImproMed projects with pharmaceutical and biotechnology companies. The focus on these collaborations is on investigating mechanisms of drug action (MoA) and identification of on- and off-target proteins to understand potential adverse effects of drug candidates on a molecular level. This can be easily carried out in the lead optimization process, or even earlier to increase the probability of success later on in the clinic.

caprotec.com

Capsulution Pharma AG Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precise-ly sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.

capsulution.com

Celares GmbH Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of Biopharmaceuticals with polyethylene glycol in order to substantially improve phar-macological properties. Offers the unique CelaSYS-PEGylation technology, which is patented by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol based reagents. Additionally celares offers customized PEGylation solutions as well as synthesis of customized PEG-reagents.

celares.com

Cell Medica GmbH Cell Medica develops, manufactures and markets personalized cellular immunothera-peutics for infectious disease and cancer.

cellmedica.co.uk

50

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

CellServe GmbH CellServe is a service provider for research groups in regenerative medicine and fills an important gap in the conversion of applied treatment concepts from research into mar-ketable products. Furthermore CellServe develops own innovative cell-based products for cardiology and uses novel cardiac derived cells ("From the Heart to the Heart") for the treatment of chronic heart failure.

cellserve.de

CellTrend GmbH Celltrend is certified according to ISO 9001, ISO 13485 and GMP Cell culture systems for research on active substances (bioassays, preclinical research, for quality control)Development and production of antibody-based detection systems (ELISA) Chemo-sensitivityassay for optimisation of chemotherapy (tumor patients).

celltrend.de

Chemicell GmbH Chemicell develops and produces magnetic, fluorescent and coloured nano- and mi-croparticles, reactive fluorescent dyes and special chromatography-materials for the separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems.

chemicell.com

Chipron GmbH Chipron GmbH specializes in production and distribution of array based detection sys-tems for DNA/pathogens.

chipron.com

CHIRACON GmbH chiracon is a qualified partner to develop chiral intermediates at a constant high quality for innovative drugs regarding economic, environmentally acceptable and scaleable aspects. We offer support through expert knowledge and key technology to meet your increasing needs. Our core competence is chirality. In addition we have a broad variety of chiral building blocks as an inhouse raw material source for high-level API production and development.

chiracon.de

CMZ-Assay GmbH Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and their isoforms, exclusively for research purposes.

cmz-assay.com

co.don® AG co.don® AG is one of the leading biopharmaceutical companies in the area of Regen-erativeMedicine/Tissue Engineering. Since 1997, co.don® AG has developed, manu-factured anddistributed human Tissue engineering therapeutics for the regeneration of articular cartilage and intervertebral discs.

codon.de

CONGEN Biotechnologie GmbH CONGEN is specialized in food testing by molecular analytics based on DNA and RNA detection. CONGEN has been a pioneer for over a decade in the development and application of food and feed analytics by real-time PCR. The methods are available as complete analytic kit as well as a Service. Our mission is to serve the food industry with an excellent service and with standardized and reliable test kits in order to realize highest possible food safety and food quality.

congen.de

Cyano Biotech GmbH Cyano Biotech identifies and characterizes natural products from cyanobacteria and optimizes their pharmacological activities employing a biocombinatorial approach. The company conduct further development of identified lead structures till the preclinical phase.

cyano-biotech.com

DendroPharm GmbH DendroPharm, a spin-off from the Free University of Berlin, develops innovative cus-tomized to drugs nanocarriers, which allow active pharmaceutical ingredients more focused and objective to bring: in tumor tissue, cartilage or into the skin.

dendropharm.de

DexLeChem GmbH We are experts in the reactivation of complex chiral catalysts. For the first time the unmodified homogeneous catalyst can be re-used repeatedly thanks to our innovative water based process. Supported by quantum chemical analysis we are able to simulate catalytic cycles. Combined with our special knowhow this enables us to find the best solvent system for our customers. By using this new resource-efficient reaction route our customers – manufacturers of active pharmaceutical ingredients (APIs) and fragrances – gain two advantages: reduction of production costs and a more sustainable process.

dexlechem.com

Diaglobal GmbH Development, production and distribution of in vitro-diagnostics for analytical purpose and the distribution of medical products.

diaglobal.de

DIZG Deutsches Institut für Zell- und Gewebeersatz gemeinnützige GmbH

DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preservation as well as in cell and tissue replacement, and provides tissue preparations of human origin to clinics, teaching and research organisations. Further service is cul-turing of skin cells (keratinozytes) for serious burns and other skin defects not healing well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation with animals e.g. in the cosmetics industry.

dizg.de

Dr. Götz Verfahrenstechnik Biotechnik Umwelttechnik

Contract research and contract manufacturing using bacteria, yeasts and fungi. drgoetz.de

Dr. Lerche KG Innovative company engaged in development, production and marketing of special-ized microcapsules for bio- and medical technology - Development and production of novel DNA-Purification-Kits with proprietary technology - Production and marketing of microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for blood analysis (Sedi-Val ESR standards) - Encapsulation of cells - Contract analysis for characterization of microcapsules, porous membranes and hollow fibres.

lerche-biotec.com

Dr. Otto GmbH Handling with research and development of ecological products its process of devel-opment also its production and marketing - Production and refinement of plantingre-dients - Operate an analytical laboratory of renewable resources and chem. Analysis.

dr-otto-gmbh.de

Dr. Rölleke Labor für Genetische Analytik GmbH

Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts and the private sector.

dr-roelleke.de

51

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

Drug Response Dx GmbH DRDx makes drug response predictable: Challenge and necessity of personalized medicine and individualized therapies demand for convincing and reliable companion diagnostics. The first field of activity of DRDx is Rheumatoid Arthritis (RA). The goal of our company is the technical and clinical validation of an IVD test kit for the reliable prediction of therapy response to TBAs ahead of treatment.

drdx.de

E.R.D.E.-AAK-Diagnostik GmbH E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for com-mercial purposes.

aak-diagnostik.de

EMP Biotech GmbH Production of fluorescent dyes and chemiluminescent reagents. Contract chemical synthesis of small molecules. Contract labeling and purification of proteins, antibodies and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Pro-duction of high quality reagents for DNA synthesis.

empbiotech.com

Epigenomics AG Development and commercialization of innovative molecular diagnostic test products based on DNA methylation for cancer screening and for cancer specialty applications.

epigenomics.com

Epinamics GmbH Epinamics GmbH, a newly established Berlin based pharmaceutical research and development dedicated company, is owner of a proprietary film forming formulation technology platform, the ?Invisible Patch? system. The system is offering a broad basis for the development of formulations for treatment of dermatological diseases as well as for the development of transdermal systems.

epinamics.com

Epiontis GmbH Establishing methylation fingerprinting as Gold Standard for quality control in Regener-ative Medicine and Immunomonitoring.

epiontis.com

Epo Experimentelle Pharmakologie & Onkologie GmbH

The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer is a specialized market segment. Using the equipment available, all experimen-tal techniques can be carried out in first-rate quality. That means that EPO is an attrac-tive partner for the drug development section of large pharmaceutical companies, for partners from the Biotech industry and for research institutions.

epo-berlin.com

Eternygen GmbH Eternygen is a Berlin based start up founded in June 2012 focusing on research, de-velopment and marketing of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen´s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades.

eternygen.com

Eurovir Hygiene-Institut/Dr. Thraenhart

Laboratory service for testing the efficiency of products against viruses (virucides) and of processes for inactivating or eliminating viruses (virus safety).

eurovir.de

EVESTRA GmbH EVESTRA is a newly founded biotech company focusing on developing female health products. The companies expertise resides with steroid chemistry and biology. EVES-TRA’s product pipeline includes products for contraception, hormone replacement ther-apy, gynecological disorders and hormon dependent cancers.

evestra.com

F.A.T. Forschungsinstitut für Antioxidative Therapie GmbH

Measuring instruments and kits for evaluating the antioxidant properties and the degree of oxidative damage in biological substrates.

antioxidant-research.eu

Fermtec GmbH Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fermentation, innovative foods and beverages and auxiliary substances for the food industry.

fermtecgmbh.de

FILT Lungen- und Thoraxdiagnostik GmbH

Development of innovative, non-invasive diagnostic methods in the area of respiratory diseases and allergies.

filt.de

Formula GmbH Galenical development of liquids and solid formulations Lyophilization Technolgy also apllicable for biochemical products Granulation, drying and coating using fluid bed drying-technology, tabletting Development and validation of analytical methods includ-ing UPLC Stability testing (ICH / GMP related to on going) Import of medicinal poducts from non-EU-countries, manufacturing, quality control (re-test) and release for market in accordance with §16 AMWHV for medicinal products and clinical supplies GMP-cer-tificat / Manufacturing license in accordance with §13 AMG.

formula-pharma.de

G&Life SpA G&life provides personalized strategies based on genetics. The life-science company is made up of a multi-disciplinary team combining expertise in genetics, nutrition, sport and engineering to develop products and services aimed at improving the quality of life.

glifecompany.com

GA Generic Assays GmbH Development, manufacturing and distributing of in vitro-tests, focussing on autoimmune diseases, hereditary and infections diseases.

genericassays.com

Gene Analysis Service GmbH Gene Analysis Service is specialized on genetic testing of a number of rare hereditary diseases and provides nucleic acid based molecular biological services like PCR and custom DNA sequencing for healthcare providers and research institutes worldwide.

gene-analysis-service.de

GenExpress Gesellschaft für Proteindesign GmbH

GenExpress is a flexible company providing services in molecular biology. For over a decade we have successfully worked for customers in clinical laboratories, research institutions and the industry. We offer cloning of PCR targets, preparation of synthetic genes, expression of proteins, evaluation of LightCycler® assays, furthermore produc-tion of internal controls and standards for Real Time PCR systems, also cloning, expres-sion and purification of proteins.

genexpress.de

52

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

GILUPI GmbH GILUPI is a medical diagnostics company with an initial focus on the prenatal and can-cer market. The company is developing an innovative new diagnostic product based on nanotechnology. Our goal is to catch specific cells, which can be found only in very low concentration in the blood. The first application for our new nanosensor device will be prenatal diagnoses of chromosomal aberration out of maternal blood. The second application will focus on the early diagnosis of cancer.

gilupi.com

GlucoMetrix PVS GmbH The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus-aftermath. At the foreground of research and development is the enhancing the quality of life of diabetics. In addition, the life science company develops some IT-based diagnostic procedures and medical devices as well as biopharmaceuticals and other highly effective products in order to raise the quality of life of diabetics sus-tainably.

glucometrix.de

Glycon Biochemicals GmbH Production of carbohydrate components used for the synthesis of new pharmaceutical compounds or diagnostics.

glycon.de

Glycotope GmbH Glycotope is a leading company in glycomics and immunotherapeutics. It has devel-oped novel therapeutic antibodies and unique platform technologies to optimize the gly-cosylation of new biological entities. Glycotope Biotechnology, with 25 years of experi-ence in GMP-production, enables us to offer the entire process of biopharmaceutical development with a dedicated focus on our unrivalled expertise in protein glycosylation from the gene to production and fill & finish of clinical grade material.

glycotope.com

GlycoUniverse GmbH GlycoUniverse GmbH & Co KGaA is a technology spin-off of the Max Planck Institute of Colloids and Interfaces. Registered on 10th October 2013, the company deals with the automated development and synthetic production of complex sugars and is seeking customers and collaboration with leading scientific institutes in Europe and world-wide.

glycouniverse.de

Götz Protein Engineering Offering a wide range of protein technology up to the final purified protein. goetz-protein-engineering.de

HealthTwiSt GmbH HealthTwiSt is a service provider for “Genetic Contract Research” in the fields of Func-tional Genomics, Epigenetics, Proteomics or Functional Food / Nutriceuticals. In par-ticular, HealthTwiSt is offering access to extensively characterized human subjects and samples as well as prospective studies in twins, together with know-how in the analysis of complex genetic traits. Furthermore, database development, data management and statistical analyses for clinical projects are provided.

healthtwist.de

HF Biotec Berlin GmbH Development, selling and operating of digestion plants using liquid substrates of indus-trial and agricultural provenience, Development and operating of combined plants to upgrade biogas into bio methane useable in public gas grids with parallel production and selling of high quality PCC, Development of innovative biotechnological processes and plants.

hf-biotec.com

Hybrotec GmbH Hybrotec GmbH is specialized in the development of monoclonal antibodies and im-munoassays (preferably homogenous assays) as customs service. Our main focus lies on antibodies binding low molecular weight substances (e.g. toxins, fluorophores, hor-mones) as well as antibodies against novel proteins.

hybrotec.com

ICI GmbH ICI – immunochemical intelligence gmbh – is dedicated to the development and pro-duction of innovative immunoassay components and kits for research use. Their goal is to provide individual solutions, exactly tailored to the client’s needs and to create lasting relationships by providing outstanding services and high quality products to demanding clients.

ici-diagnostics.com

Icon biotech Icon biotech is an innovative biotechnology company, which uses the extraordinary characteristics of Ciliates for the development of bio-analytical and toxicological model systems.

icon-biotech.com

IDrug GmbH IDrug supports business strategies with innovative methodologies in analytical and bio-pharmaceutical chemistry

idrug.de

Ifp Institut für Produktqualität GmbH

Ifp Institut für Produktqualität is a laboratory and competence centre for state-of-the-art food, drinking water and pharmaceutical analysis. The accredited and GMP-certified company focuses on comprehensive services for the food and pharma industry. An additional core competence of ifp is the development and production of innovative diagnostics comprising the real-time PCR kits of the brand “mericon” (QIAGEN), vita-min tests in microtiter plate format, enzymatic microtiter plate kits for sugars/acids, and allergen tests in lateral flow and ELISA formats.

produktqualitaet.com

IGV Institut für Getreideverarbeitung GmbH

The range of services offered by the Biotechnology Division of the private research IGV GmbH institute is based on 25 years of experience in R&amp,D for the cultivation of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and cosmetics and energy industry provide the fundament for innovative, market-oriented developments. In focus are development of photo bioreactor technology and active substances from algae.

igv-gmbh.de

IKDT Institut Kardiale Diagnostik und Therapie GmbH

IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laborato-ries on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a limited number of specialized cardiological labs worldwide. Its service enables physicians firstly to start an efficient, pathophysiologi-cally based causal therapy.

ikdt.de

53

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

ILBC GmbH Research, consulting, production, trade & services in the areas biology, molecular bi-ology and protein chemistry - Expression and production of antimicrobial peptides.

mobiclup.de

ImaGenes GmbH RZPD spin-off, today part of Source BioScience plc, a premier service center for ge-nome research and healthcare in Europe, provides one of the largest clone collections in the world via its clone search engine GenomeCube®. Certified Service Provider for illumina Next Generation Sequencing services and comprehensive microarray applica-tion on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified.

imagenes-bio.de

In.vent DIAGNOSTICA GmbH in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the proj-ect-oriented provision, processing and distribution of biological raw material for de-velopment and production of diagnostics and control material. We are your reliable partner for the customised development of assays for medical in vitro-diagnostics.

inventdiagnostica.de

inbion GmbH inbion GmbH provides services to support research in the interface between university, students and industry. For companies, we provide the benefit of outsourcing projects quickly and cost-efficiently to competent teams. Cooperation with research groups in the university is also facilitated, so that targeted knowledge transfer can take place here.

inbion.de

Innovative Optische Meßtechnik GmbH

Fluorescence Assay Solutions and Instrumentation (Microplate Readers). iom-berlin.de

Institut für Medizinische Molekulardiagnostik (IMMD) GmbH

Gene tests for prenatal, predictive and tumor -diagnostics. immd.de

Institut für Molekular- und Systemmedizin I.M.S.M. GmbH

Scientific-practical works in the area of System medicine with the purpose of the pat-enting of new treatment methods, e.g. to the treatment of diabetes. International coop-eration in this area.

InterMune GmbH InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

intermune.de

InVivo Biotech Services GmbH As a contract manufacturing company (CMO) Invivo offers a wide range of services: the development and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documen-tation), cell line development and transient transfection. We are an ISO9001:2008 cer-tified company.

invivo.de

InvivoContrast GmbH InvivoContrast provides globally high quality MRI (Magnetic Resonance Imaging) con-trast agents and professional support for preclinical imaging in academic and com-mercial institutions.

invivoContrast.com

JPK Instruments AG JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - par-ticularly atomic force microscope (AFM) systems and optical tweezers - for a broad range of applications reaching from soft matter physics to nano-optics, from surface chemistry to cell and molecular biology. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nan-otechnology for transforming life sciences and soft matter research.

jpk.com

JPT Peptide Technologies GmbH JPT is an ISO 9001:2008 certified provider of innovative peptide products and services and a partner for research projects focusing on the development of novel immune therapeutics & diagnostics, profiling of various enzyme classes and proteomics. JPT has developed a portfolio of proprietary technologies and a series of unique products which support a worldwide customer base. Since 2011 all catalog products such as peptide microarrays & peptide pools are avalaible through an online shop.

jpt.com

KNAUER - Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH

KNAUER UHPLC and HPLC systems as well as columns are used in research and development, quality control and production plant laboratories around the world. Cus-tomers are typically governmental and industrial organizations as well as universities. Fields of application are wide-ranging and include pharmaceutical and medical re-search, analysis of foodstuffs and cosmetics, as well as environmental analysis. With our biochromatography solutions we focus on high resolution separations.

knauer.net

L.U.M. Gesellschaft für Labor-, Umweltdiagnostik & Medizintechnik mbH

Analysis, diagnosis and sensor technology as well as stability, rheology and segrega-tion behavior of dispersions.

lum-gmbh.de

labfolder GmbH labfolder is a digital notebook and collaboration platform for laboratory research. As a viable alternative to traditional paper-based laboratory notebooks, labfolder allows sci-entists to document and organize their research, plan their experiments and collaborate with others digitally. The software provides an intuitive user interface and is compliant with the rules of Good Scientific Practice (GxP), including full audit trail and digital signatures for maximum intellectual property protection. labfolder is also available on all mobile devices operating under Android and iOS, allowing scientists to access and manage their data from everywhere. labfolder is free for individual scientists and small groups and offers advanced functions for large research groups and enterprises for a monthly fee.

labfolder.com

54

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

Labor Berlin – Charité Vivantes Services GmbHLabor Berlin – Charité Vivantes GmbH

Labor Berlin Services is the service subsidiary of Europe’s largest hospital laboratory for clinical pathology and offers complete solutions for any kind of testing for the ivd industry, CROs, the pharmaceutical industry, life science companies and research fa-cilities, while Labor Berlin is the exclusive laboratory partner of Charité - Universitäts-medizin Berlin and the Vivantes Network for Health. Labor Berlin and Labor Berlin Ser-vices both perform over 35 million analyses in clinical pathology per year and provide the diagnostic services for approximately 400.000 in-house patients a day and some one million out-patients per year.

laborberlin.com

LGC Genomics GmbH LGC Genomics is the division of LGC with specific expertise in high quality, cut-ting-edge genomic and related services and products. LGC Genomics delivers:- Next generation sequencing services- DNA sequencing- Genomics services- Nucleic acid extraction services- DNA extraction products. LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and refer-ence standards (lgc.co.uk).

lgcgenomics.com

LGC GmbH Production of calibration substances for purity testing of drugs. mikromol.de

Life Glimmer Life Glimmer is a customer-oriented consulting and contract research company with the goal of providing the biotechnological, biomedical and environmental research communities an efficient way to outsource scientific modeling and computing needs.

lifeglimmer.com

Limetec Biotechnologies GmbH The core competence lies in the development of high-speed and high-quality proof systems for the detection of pathogens, as well as in the allelic discrimination of he-reditary diseases. All products are marked with the CE-Certificate. The second area of expertise is the creation of communication networks which connect out-patient and hospital patient treatments, intensify data exchange and provide information to all health institutions, thus establishing partner relationships between them.

limetec-biotechnologies.de

Lipidomix GmbH LC/MS/MS based high trouput analytic of lipid mediators and metabolites. Analytical method development, analytical support for LC/MS/MS in life science, food safety, fo-rensic science.

lipidomix.de

MagForce AG MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company’s proprietary procedure, NanoTherm® therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via ac-tivation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

magforce.com

Marinpharm GmbH Development and marketing of genetically altered cell lines on the basis of new fluores-cence markers. Generation of stably transfected fluorescent cell lines.

marinpharm.com

MedInnovation GmbH MedInnovation GmbH has developed a new method and a special ESR-analyser, which for the first time allows a simple routine laboratory test for evaluation of functional char-acteristics of plasma proteins and further opens a reliable possibility for cancer diag-nostic, named MMS-technology (mobility of molecular structure).

medinnovation.de

Medipan GmbH Development, manufacturing and international distribution of radioactive (125J-IRMA) and non-radioactive (Elisa) in vitro-diagnostic tests, covering the field of Autoimmunity, mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immu-nofluorescence tests by the AKLIDES system.

medipan.de

MerLion Pharmaceuticals GmbH The business purpose of the Company is the research, production, optimization and the development by way of pre-clinical as well as clinical trials of new molecules for the treatment of infectious diseases.

merlionpharma.com

Merz Pharmaceuticals GmbH / Standort Potsdam

Merz is one of the leading research-based health care companies. Merz Pharmaceu-ticals has achieved a leading position in Alzheimer’s research with the world’s first drug for the treatment of moderate to severe Alzheimer’s disease. With high quality products from tetesept® and Merz Spezial®, Merz is making a key contribution to health and wellbeing.

merz.de

Metabolomic Discoveries GmbH Metabolomic Discoveries is an analytical service and research company. We provide mass spectrometry based metabolite profiling and fingerprinting of biological material, as well as single compound measurements.

metabolomicdiscoveries.com

Metanomics GmbH Metabolite Profiling for identification of gene function relationship in plants, metabolite biomarkers and metabolic networks.

metanomics.de

Metanomics Health GmbH Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nutrition.

metanomics-health.de

MetrioPharm AG MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new and innovative medicines.

metriopharm.com

Mfd Diagnostics GmbH The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and develop-ment company for diagnostic and therapeutic application of innovative laser technolo-gies. The main advantages of the developed technologies are the non-/minimally-inva-sive measurement methods, the non-artificial approach and the possibility of real-time measurement. Therefore, those are promising tools for the diagnosis and therapy mon-itoring in the neurological practice and in the perinatal surveillance.

mfd-diagnostics.com

55

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

MicroDiscovery GmbH MicroDiscovery GmbH is a leading provider of high quality software for biomolecular research, innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a strong track record in creating software systems in accordance with relevant regulatory directives for the life science and IVD industry. Customised services ranging from biostatistical data analysis to bioinformatical design and support of com-plex research projects complete the product line of MicroDiscovery.

microdiscovery.de

Microparticles GmbH Development, manufacture, surface modification and characterization of mono-disperse polymer particles in the nano- and micrometer range. In addition to classic polystyrol and polyacrylate-based polymer particles, microparticles GmbH has launched new melamine resin particles on the market with exceptional chemical and physical quali-ties. The main areas of application are in particle measurement technology, medicine, biochemistry and microelectronics etc.

microparticles.de

Minerva Analytix GmbH Minerva Analytix GmbH is a leading analytical service lab for the control of microbial contamination. Our core competence lies in the control of mycoplasma, bacteria and viruses in cell cultures and biopharmaceuticals

minerva-analytix.com

Minerva Biolabs GmbH Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for contamination control, especially mycoplasma in cell cultures and biopharmaceutical products. Minerva Biolabs is also active in ensuring water quality with sensitive pro-cesses for detecting legionella. Our distributors ensure that our products are available worldwide, quickly and at a good price.

minerva-biolabs.com

mivenion GmbH mivenion is a life-science company founded in Berlin aiming on the development and commercialization of diagnostic and therapeutic products. The company is built on two innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging of early rheumatoid arthritis and a proprietary bioactive polymer drug development platform. Xiralite is mivenion´s first product on the market.

mivenion.com

MLB Mikrobiologisches Labor GmbH

Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, D-PL-13398-01-00, EN 17025. Accreditation according to VDI 6022.

mikroberlin.de

Molnar-Institut für angewandte Chromatographie

Molnar-Institute, established in 1981, offers you a complete scientific and technical service for all problems concerning Quality by Design (QbD) for HPLC-methods. We develop for you the Design Space for your HPLC-separation and establish Critcal Qual-ity Attributes (CQA’s). We offer detailed DryLab-courses and show you, how to develop robust methods in the Design Space and how to save time. We supply and implement the DryLab-software and train your coworkers. We assist you in automated method development processes and support you in the selection of proper instruments, their installation and use.

molnar-institute.com

MOLOGEN AG MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases. The proprietary platform technologies MIDGE® and dSLIM® build the foundation for all business activities. The company was founded 1998 and was one of the first biotechnology companies to go public.

mologen.com

moloX GmbH moloX GmbH is a company focusing on custom protein production in bacterial and in-sect cell expression systems and subsequent protein purification to ultra-high purity. On customer demand a team of experts can perform protein crystallization experiments and determine the 3D structure of target proteins by X-ray crystallography.

molox.de

MRI.TOOLS GmbH MRI.TOOLS´s main focus is the development, sales and services of innovative hard-ware and novel technology for magnetic resonance imaging (MRI), computed tomogra-phy (CT) and positron emission tomography (PET). Our product portfolio encompasses enabling radiofrequency (RF) coils tailored for a broad range of applications, devices designed for reliable cardiac gating of imaging plus accessories that will make your daily life more comfortable. MRI.TOOLS is also very proud to offer consulting services such as validation and certification of medical devices.

mritools.de

Myelo Therapeutics Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet med-ical needs.

myelotherapeutics.com

Nano Access Technologies Ltd. The company addresses the combined access to key technologies such as life science and nanotechnology. As a first product, a low cost AFM for operation with so-called ac-tive cantilevers has been developed. Besides this, functionalized cantilevers for future biosensors are another focus of the company.

nano-access.com

Nanolytics Gesellschaft für Kolloidanalytik mbH

We are a contract laboratory specializing in the physico-chemical characterization of pharmaceutical proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are Analytical Ultracentrifugation, in combination with Static and Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermody-namic techniques (ITC, DSC).

nanolytics.de

Nanopartica GmbH Nanopartica GmbH optimizes existing products of other companies, but are also devel-oping new products and materials. In particular, companies in surface-, bio-, and medi-cal-technology can benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, plati-num), or ions. This will indirectly change the guests properties and expands its scope.

nanopartica.com

56

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

nanoPET Pharma GmbH As a technology and service provider to the biopharmaceutical industry nanoPET fo-cuses on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging based on novel nanoparticular materials. nanoPET offers consulting and contract research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as catalog items and pursues the preclinical development of its patented core technology of inorganic nanoparticle PET tracers.

nanopet-pharma.com

NovaBiotec® Dr. Fechter GmbH Microbiological and chemical investigations, in particular of soil, water and air samples, planning / inspection of sanitation, in particular analytics and sanitation support for mould and dry rot, incl. education in this field. Delivery of production auxilliaries and support for biogas plants with biological treatment processes incl. application, insula-tion and preservation of enzymes. Research, development and marketing of test kits for breweries and malthouses.

novabiotec.de

NOXXON Pharma AG NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics: Spiegelmer® NOX-E36, Spiegelmer® NOX-A12, Spiegelmer® NOX-H94. The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature biotech company with a strong syndicate of inter-national investors, approx. 60 employees and a highly experienced management team.

noxxon.com

OakLabs GmbH OakLabs provides the most flexible products and services for large scale custom SNP genotyping on the market. OakLabs offers several formats for analysing a variable num-ber of SNPs in any sequenced organism.

oak-labs.com

OctreoPharm Sciences GmbH OctreoPharm Sciences GmbH is a clinical development company focusing on diagnos-tic radiopharmaceuticals.

octreopharmsciences.com

Omeicos Therapeutics GmbH OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of ome-ga-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other an-ti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.

omeicos.com

OpTricon Entwicklungsgesellschaft für optische Technologien mbH

OpTricon develops and produces mobile readers for quantitative analyzes of Immuno-assays for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for lbioanalytics. opTricon develops the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008.

optricon.de

ORGANOBALANCE GmbH ORGANOBALANCE is a company specializing in microbial strain development and screening. As a R&D contractor ORGANOBALANCE develops new biological products in the areas of nutrition, personal care and health care. The company draws on its own collection of microbial strains suitable for food applications and its OASSYS® bioassay systems. In the field of “metabolic engineering” ORGANOBALANCE exploits Saccha-romyces cerevisiae yeast for synthesis of substances for the industrial and pharma-ceutical industry.

organobalance.com

ORGANOBALANCE Medical AG ORGANOBALANCE Medical AG funds and promotes the research and development of novel therapies based on specific probiotic cultures, aiming to develop active sub-stances and mechanisms for innovative medicinal products and medical devices, as well as offer new therapeutic concepts for hitherto inadequately treatable indications.

organobalancemedical.com

ovalehn GmbH Production and application of specific recipes -containing IgY for diagnostics and oral, passive immune therapy.

ovalehn.de

Pentracor GmbH In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the primary damage. Based on a new prototype, the company Pentracor GmbH aims to develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its certified production and market the product after clinical validation.

pentracor.com

Peptides&elephants GmbH Custom synthesis of peptides and peptide libraries Development parallel Synthesis technologies Distributor of Peptide Synthesis Automation.

peptides.de

PharmaSol GmbH Modification of ingredients or introduction of new metabolic pathways in plants with gene-technology methods.

pharmasol-berlin.de

PlasmaChem GmbH PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in nanomaterials, plasma- and ultra-thin film technologies. The company manufactures nano-coated medical implants (stents), nanomaterials, additives for metal plating (ap-plied e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds and other industrial nanoproducts.

plasmachem.com

57

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

PolyAn, Gesellschaft zur Herstellung von Polymeren für spezielle Anwendungen und Analytik mbH

PolyAn is specialised in Molecular Surface Engineering (MSE). Using our surface modi-fication expertise PolyAn optimises the performance of analytical systems by improving the signal-to-noise ratio as well as the reproducibility of consumables for multiplex diag-nostics, LifeScience research and screening applications. PolyAn?s product portfolio includes functionalised microarray slides, microparticles for multiplex bead arrays and functionalised membranes for medical diagnostic applications.

poly-an.de

Preclinics Gesellschaft für präklinische Forschung mbH

Preclinics is a commercial cooperation partner for preclinical research and develop-ment. As a competent, creative and experienced partner preclinics investigates phar-maceutical substances, therapeutic methods and proceedings as well as medical products during the preclinical phase. Additional we provide custom antibody produc-tion in llama, goat, sheep, rabbit and other species.

preclinics.com

Predemtec GmbH Predemtec GmbH is a company focused on the research, development and manu-facture of innovative diagnostic tests for use in the detection of dementia-related risk factors. The goal has been to make the early and reliable diagnosis of various demen-tia-related illnesses a reality through the use of our innovative diagnostics tests.

predemtecDX.com

ProBioData GmbH BioProcessDB is a database solution for bioprocess R&D. It's designed to become the linking tool in your information process and to integrate the data i. e. from the SCADA system, the sample data management and the strain management.

probiodata.de

ProBioGen AG ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and Technology Provider, with extensive expertise in cell line engineering, process devel-opment (upstream- and downstream process) and GMP manufacturing of biopharma-ceuticals. Offering state-of-the-art contract development and manufacturing services as well as access to proprietary cell lines (AGE1.cell lines®) for the manufacturing of biopharmaceuticals and vaccines. The company possesses the manufacturing autho-rization from the competent authority and meets the quality standards required by the EMA and the FDA guidelines.

probiogen.de

ProteaImmun GmbH ProteaImmun is a specialized proteomic company providing purified human proteins, antibodies and ELISAs. Our proteins are designed for structural and functional stud-ies of proteases screening and evaluation of protease inhibitors and modulators. Fur-thermore we develop highly sensitive ELISA kits and antibodies. Our Focus: MMPs, ADAMTs, HtrAs. ProteaImmun produces a unique range of recombinant proteases for medical and pharmaceutical research. The main focus is on human Matrix Metallo-proteases (MMPs), ADAMTS and HtrA proteins which play an important role in neuro-degenerative disease, ancer and arthritis. Customer Service: ProteaImmun provides activity analysis by zymography adapted for MMPs.

proteaimmun.net

PROTEKUM - Umweltinstitut GmbH, Oranienburg

We plan to eliminated fluid und solid waste products in a manner which is compatible with environment protection. Our methodology is largely based on painstaking analysis. We use modern equipment and scientific methods. Protekum offers high-quality prod-ucts and services in environmental analysis redevelopment.

protekum.de

Proteome Factory AG Biomarker & target discovery, validation, analysis of food and ingredients, absolute quantification of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, pharmaco, immuno and membrane proteomics, protein identification, characterization of proteins and peptides (PTMs, e.g. phosphorylation, glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver staining kit etc.

proteomefactory.com

Provitro GmbH Provitro combines more than ten years of experiences in commercialisation of cell culture technologies, Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management system according to ISO 9001:2008, we provide our customers not only with high-quality products, CE marked in vitro-diagnostics and state-of-the-art services but also with individual solutions for their specific requests.

provitro.de

Rapidozym Gesellschaft für Laborhandel und DNA Diagnostika mbH

Expertise of cell biologists cell manufacturing and clean room technology specialists. Focuses on clinical stem cell product development portfolio are stroke, myocardial in-farction and plastic surgery.

rapidozym.de

RENESA UG (haftungsbeschränkt)

Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of Care Testing).

renesa.de

RiNA GmbH RiNA has developed systems for cell-free protein biosynthesis based on pro- and eu-karyotic cell lysates. A synthesis service is realised in RiNA’s own laboratories and complements the EasyXpress Kits (Qiagen). The purchase of Roche´s RTS-products enables RiNA now to be a key player in the field of cellfree biosynthesis with a large variety of products. Another research focus is the development of aptamers (DNA and RNA) for biosensors.

rina-gmbh.eu

RIPAC-LABOR GmbH RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poul-try, pigs and cattle, but also in other farm and domestic animals. The company uses pathogen differentiation to provide quick and effective methods for fighting pathogens. It performs resistance tests and epidemiological analyses and also focuses on produc-ing herd-specific vaccines.

ripac-labor.de

Roboklon GmbH Distribution, Marketing and Development of Products for Molecular Biological Research and Genetic Engineering.

roboklon.de

58

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

ROVALAB GmbH Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our high quality critical raw materials and reagents such as DNA Polymerases and dNTPs are designed to help you successfully and rapidly solve your scientific and manufac-turing tasks.

rovalab.com

Royal Biotech GmbH Royal focuses on developing, manufacturing and marketing innovative kits, portable or micro-structured systems, and the next generation of diagnostic chips for near re-al-time environmental, food safety, disease and laboratory diagnostics.

royalbiotech.com

Scienion AG Scienion is a life science company in the markets of dispensing systems and microar-ray technologies. The product portfolio comprises hardware, consumables and ser-vices. Scienion’s leading product is the sciFLEXARRAYER dispensing system, available in a product line of six size versions. The dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and non-contact micro drop delivery in the picoliter to microliter range onto a variety of carriers.

scienion.de

Sepiatec GmbH Production, development and sales of automated HPLC machines for high-throughput purification and fractioning of complex substance compounds.

sepiatec.com

Seramun Diagnostica GmbH Seramun offers peptide synthesis, purification and conjugation of proteins, production of antibodies, customer research, in vitro-Diagnostics. We focus on the development and production of enzyme immunoassays for diagnosis of viral and bacterial infections and autoimmune diseases of the gastrointestinal tract, the development of multi-pa-rameter assays as microtitre plate assays and as membrane immunoassays, as well as development of ready-to-use substrate solutions and for protein stabilizers.

seramun.com

SGS INSTITUT FRESENIUS Berlin GmbH & Co. KG

Analytical laboratory services and consulting for development, production and quality control of drugs.

institut-fresenius.de

SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin

Development, production and purification of monoclonal antibodies for use in diag-nostics. Development and production of blood grouping reagents, Serafol® bedside cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. Development and production of culture media for microbiological diagnosis.

sifin.de

Signature Diagnostics AG Signature Diagnostics is dedicated to the discovery, validation and commercial de-velopment of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient selection and stratification based on molecular gene signatures will soon become an important component of routine cancer treatment.

signature-diagnostics.de

Silence Therapeutics AG Silence Therapeutics AG is a leading RNAi therapeutics development company and offers a novel, proprietary siRNA technology (AtuRNAi) and proprietary systemic de-livery systems for siRNA (AtuPLEX, DACC and DBTC). SILENCE pipeline consists of both partnered and internal programs of which 3 clinical phase II and 1 clinical phase I programs are partnered with Pfizer/Quark (2 ophthalmic indications) and Novartis/Quark (2 kidney indications). Silence?s internal lead compound Atu027 is currently in a Phase I clinical study for the treatment of solid tumours.

silence-therapeutics.com

SINA Science Services GmbH SINA is a modern company providing elaborate services in molecular biology and protein biochemistry. Together with our industrial partners and customers from re-search institutions we develop complex cloning and mutagenesis strategies including high-throughput applications. We offer cloning of genes, expression and purification of proteins, DNA and RNA isolation from numerous biological materials and the production of competent cells with high transformation efficiency.

sina-science-services.de

SLM- Speziallabor für angewandte Mikrobiologie GmbH

Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drink-ing water, foodstuff, monitoring in clean rooms.

speziallabor.com

Sopat GmbH SOPAT is specialized in the analysis of particulate systems. The company develops and markets an innovative particle measurement technology for real-time analysis of multi-phase systems. Particles, such as droplets, grains, cells or bubbles, are measured with high precision in running processes.

sopat.de

STRATEC Molecular GmbH STRATEC Molecular GmbH is a globally active provider of innovative system solutions for nucleic acid sample collection, stabilization, and both manual and automated puri-fication from any sample type. Since 1992 the company is internationally respected for its outstanding and high performance technology platforms and offers a broad spec-trum of superior products for molecular diagnostics, drug discovery and Life Science research.

invitek.de

Strix Diagnostics GmbH Strix Diagnostics is a medical diagnostics company specializing in customized devel-opment of certified analytical systems for multiparameter in vitro-diagnostics.

strix-diagnostics.de

Surflay Nanotec GmbH Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is spe-cialized on coating colloidal and planar materials with functional films. Key technology is the patented LbL-Technology® with polymers. Applications are in the fields of separa-tion materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition to customer tailored projects Surflay offers an unique range of products of tunable multifunctional nano-or microparticles and dye-labeled polymers.

surflay.com

59

BioTOPics 47 | May 2014 BioTOP-Report Addresses

Biotech Companies

t-cell Europe GmbH t-cell Europe GmbH, a spin-off of the Berlin Brandenburg Center for Regenerative Med-icines (BCRT), is aiming to become the world’s technology leader in the application of T-cell-based therapies used in transplantation medicine. Over the next few years, with its three proprietary platform technologies, the company will develop and clinically validate novel T-cell-based products and corresponding diagnostics to regulate the immune system and treat viral infections. The company’s lead reference product will be a first-in-class Treg cell product/therapy for kidney transplantation that suppresses organ rejection in recipients

t-cell.de

Thanares GmbH Development, use and marketing of analytical process for diagnostic and therapeu-tic purposes. Future business activities: detection process for bioactive substances in bodily fluids, isolation, characterization and investigation of bioactive compounds from plants, in particular insoluble proteins or low concentrations of proteins, development of low cost genetic systems for over-expression and/or production of such proteins.

thanares.com

TheraKine BioDelivery GmbH Development of antibody drug delivery systems and related tasks. therakine.com

Thermo Fisher Scientific – B·R·A·H·M·S GmbH

Thermo Scientific Biomarkers (B·R·A·H·M·S GmbH) explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 470 employees, in the disease ar-eas infectiology, cardiology and pneumology as well as thyroid, autoimmunity and car-diology on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S GmbH is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science.

thermoscientific.com/brahms

TIB MOLBIOL Syntheselabor GmbH

In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In addition to designing and synthesizing primers and probes for Real-Time PCR assays, we develop and produce LightMix® Kits for Roche Diagnostics LightCycler® Instruments, covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as well as Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified.

tib-molbiol.com

TissUse GmbH TissUse is a vibrant growth company providing high-value services in the area of tissue culture analysis of drug candidates, cosmetics, chemicals and consumer products.

tissuse.com

TransTissue Technologies GmbH TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since Septem-ber 2001. With more than 15 years of experience in regenerative medicine, the scien-tists of TransTissue Technologies have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions and the development of tissue engineering products for regenerative medicine. We offer a broad panel of services in the field of regenerative medicine.

transtissue.com

UGA Biopharma GmbH UGA Biopharma a private Research and Development company, focuses on Research, Development and Commercialization of Biopharmaceutical products under contract with other Biopharmaceutical companies. UGA Biopharma conducts power of biosci-ences to develop high-tech, last generation of biomedicine, diagnostic kits, molecular biology items and also offers world class services in biotechnology area.

ugabiopharma.com

Umwelttechnik-Berlin UG Feasibility studies, development, planning, construction and operation of biotechno-logical plants for groundwater, process water and waste water purification. Accredited microbiological laboratory for the investigation of drinking water, groundwater, bath water, soils, food, anti-microbial active ingredients and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German infection protection act (Infek-tionsschutzgesetz).

bartetzko.com

Zellwerk GmbH Zellwerk produces the proprietary Z® RP cell cultivation system, comprising rotating bed bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml vol-ume, 0,2-2 m² seeding surface, different cell carriers, can be delivered. In this culturing system cells grow tissue-like, being embedded in self-generated extra-cellular matrix. The technology opens unique opportunities for the GMP-compliant expansion of stem cells and primary cells, manufacturing of cell-seeded implants as well as production of recombinant proteins. In addition, we have recently developed a new bioreactor for expansion of immune cells for cell therapy of leukemia and several types of cancer.

zellwerk.biz

Zentrum für molekulare Onkologie GmbH

Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics (K-RAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - Pathology Development of new biomarkers and analytical services for studies.

molekulare-onkologie.eu

Zytomed Systems GmbH Zytomed Systems´ focus is the development, production and distribution of antibod-ies and detection systems for immunohistochemical cancer diagnostics as well as re-agents and kits for in-situ hybridisation.

zytomed-systems.de

BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the Berlin Partner für Wirtschaft und Technologie GmbH and takes part in the Cluster Management HealthCapital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European Union (European Fund for Regional Development). Investing in your Future